US5387685A - MDR reversal agents - Google Patents
MDR reversal agents Download PDFInfo
- Publication number
- US5387685A US5387685A US08/092,653 US9265393A US5387685A US 5387685 A US5387685 A US 5387685A US 9265393 A US9265393 A US 9265393A US 5387685 A US5387685 A US 5387685A
- Authority
- US
- United States
- Prior art keywords
- alkyl
- thio
- methylphenyl
- dimethoxyphenyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012313 reversal agent Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 100
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 229910052801 chlorine Inorganic materials 0.000 claims description 60
- 229910052794 bromium Inorganic materials 0.000 claims description 53
- -1 methylenedioxy Chemical group 0.000 claims description 52
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 52
- 229910052731 fluorine Inorganic materials 0.000 claims description 51
- 229910052740 iodine Inorganic materials 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 31
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 22
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 17
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 9
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 9
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- NZMGWSPYAYXUTJ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1C=2C=C(O)C(OC)=CC=2CCN1CCCCCC(C=1C=C(OC)C(OC)=CC=1)(C#N)SC1=CC=C(C)C=C1 NZMGWSPYAYXUTJ-UHFFFAOYSA-N 0.000 claims description 3
- OIGKAIXDCSOHFN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[7-(2-imidazol-1-ylethoxy)-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OCCN3C=NC=C3)=C(OC)C=C2CC1 OIGKAIXDCSOHFN-UHFFFAOYSA-N 0.000 claims description 3
- CNORTMXIZFGKGH-UHFFFAOYSA-N 2-[7-[3-(2-imidazol-1-ylethoxy)-4-methoxyphenyl]-7-(4-methylphenyl)sulfanylheptyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound COC1=CC=C(C(CCCCCCN2CC3=CC(OC)=C(OC)C=C3CC2)SC=2C=CC(C)=CC=2)C=C1OCCN1C=CN=C1 CNORTMXIZFGKGH-UHFFFAOYSA-N 0.000 claims description 3
- ACRWYXSKEHUQDB-UHFFFAOYSA-N 3-phenylpropionitrile Chemical compound N#CCCC1=CC=CC=C1 ACRWYXSKEHUQDB-UHFFFAOYSA-N 0.000 claims description 3
- WSNZXUQRDRRYMN-UHFFFAOYSA-N 5-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCN1CC2=CC(OC)=C(OC)C=C2CC1 WSNZXUQRDRRYMN-UHFFFAOYSA-N 0.000 claims description 3
- HNNRIVDZVTZPSR-UHFFFAOYSA-N 5-[7-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-1-(4-methylphenyl)sulfanylheptyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HNNRIVDZVTZPSR-UHFFFAOYSA-N 0.000 claims description 3
- FXRFXZRLIQFBBR-UHFFFAOYSA-N diethyl 6-[7-(3,4-dimethoxyphenyl)-7-(4-methylphenyl)sulfanylheptyl]-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinoline-2,4-dicarboxylate Chemical compound C1C=2C(C(=O)OCC)=C3OC(C(=O)OCC)OC3=CC=2CCN1CCCCCCC(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 FXRFXZRLIQFBBR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- IHQOGGCMRWUGRD-UHFFFAOYSA-N 10-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyldecanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 IHQOGGCMRWUGRD-UHFFFAOYSA-N 0.000 claims description 2
- IZEJYKHRRCVIEM-UHFFFAOYSA-N 13-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyltridecanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCCCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 IZEJYKHRRCVIEM-UHFFFAOYSA-N 0.000 claims description 2
- UHAROVOYHWBKDC-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)-7-(6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OCC)C(OCC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC=C(OC)C=C2CC1 UHAROVOYHWBKDC-UHFFFAOYSA-N 0.000 claims description 2
- FFKSKSAQGOOCPQ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1CCCCCC(C=1C=C(OC)C(OC)=CC=1)(C#N)SC1=CC=C(C)C=C1 FFKSKSAQGOOCPQ-UHFFFAOYSA-N 0.000 claims description 2
- YKVSFOJMOOLXOT-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[7-(2-imidazol-1-ylethoxy)-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-(4-methylphenyl)sulfanylheptanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OCCN3C=NC=C3)=C(OC)C=C2CC1 YKVSFOJMOOLXOT-UHFFFAOYSA-N 0.000 claims description 2
- PVITUUCIOROYKQ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[7-[2-(dimethylamino)ethoxy]-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OCCN(C)C)=C(OC)C=C2CC1 PVITUUCIOROYKQ-UHFFFAOYSA-N 0.000 claims description 2
- HCJPKEPIBGVGBG-UHFFFAOYSA-N 2-[6-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)sulfanylhexyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HCJPKEPIBGVGBG-UHFFFAOYSA-N 0.000 claims description 2
- QBYHJXFWLJFTMH-UHFFFAOYSA-N 2-[6-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)sulfanylhexyl]-6-methoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC(OC)=CC=C2CN1CCCCCC(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 QBYHJXFWLJFTMH-UHFFFAOYSA-N 0.000 claims description 2
- GXEBXJCYTURXIM-UHFFFAOYSA-N 2-[6-benzylsulfanyl-6-(3,4-dimethoxyphenyl)hexyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SCC=1C=CC=CC=1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 GXEBXJCYTURXIM-UHFFFAOYSA-N 0.000 claims description 2
- QFOQKQPDVPKVEX-UHFFFAOYSA-N 2-[6-cyclohexylsulfanyl-6-(3,4-dimethoxyphenyl)hexyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC1CCCCC1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 QFOQKQPDVPKVEX-UHFFFAOYSA-N 0.000 claims description 2
- GINSMERMFDOMOV-UHFFFAOYSA-N 2-[6-tert-butylsulfanyl-6-(3,4-dimethoxyphenyl)hexyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC(C)(C)C)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 GINSMERMFDOMOV-UHFFFAOYSA-N 0.000 claims description 2
- KLIWAWKHWKQIAF-UHFFFAOYSA-N 2-[7-(3,4-dimethoxyphenyl)-7-(4-methylphenyl)sulfanylheptyl]-6,7,8-trimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=C(OC)C(OC)=C(OC)C=C2CC1 KLIWAWKHWKQIAF-UHFFFAOYSA-N 0.000 claims description 2
- ADNUKJKNFPTGRR-UHFFFAOYSA-N 2-[7-(3,4-dimethoxyphenyl)-7-(4-methylphenyl)sulfanylheptyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 ADNUKJKNFPTGRR-UHFFFAOYSA-N 0.000 claims description 2
- HISOZIMXLBDOJX-UHFFFAOYSA-N 2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)-7-[7-(2-imidazol-1-ylethoxy)-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]heptanenitrile;dihydrochloride Chemical compound Cl.Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC1CCCCC1)CCCCCN1CC2=CC(OCCN3C=NC=C3)=C(OC)C=C2CC1 HISOZIMXLBDOJX-UHFFFAOYSA-N 0.000 claims description 2
- JRRLDSSCWZFHKN-UHFFFAOYSA-N 2-cyclohexylsulfanyl-7-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC1CCCCC1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 JRRLDSSCWZFHKN-UHFFFAOYSA-N 0.000 claims description 2
- SIHGUEMTKSDVOP-UHFFFAOYSA-N 4-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylbutanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCN1CC2=CC(OC)=C(OC)C=C2CC1 SIHGUEMTKSDVOP-UHFFFAOYSA-N 0.000 claims description 2
- MQIJKIPYAPWZBZ-UHFFFAOYSA-N 5-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCN1CC2=CC(OC)=C(OC)C=C2CC1 MQIJKIPYAPWZBZ-UHFFFAOYSA-N 0.000 claims description 2
- PXPALVLDMLCHHI-UHFFFAOYSA-N 6,7-dimethoxy-2-(7-phenyl-7-phenylsulfanylheptyl)-3,4-dihydro-1h-isoquinoline Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCCCCCC(C=1C=CC=CC=1)SC1=CC=CC=C1 PXPALVLDMLCHHI-UHFFFAOYSA-N 0.000 claims description 2
- HIDBFDYTSICROG-UHFFFAOYSA-N 6-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylhexanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HIDBFDYTSICROG-UHFFFAOYSA-N 0.000 claims description 2
- ZIDJRRPIOJNLKD-UHFFFAOYSA-N 6-[6-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)sulfanylhexyl]-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OCO3)=C3C=C2CC1 ZIDJRRPIOJNLKD-UHFFFAOYSA-N 0.000 claims description 2
- HLOQUFKUYZBZLI-UHFFFAOYSA-N 7-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HLOQUFKUYZBZLI-UHFFFAOYSA-N 0.000 claims description 2
- HQHLKXQAAGOVID-UHFFFAOYSA-N 7-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HQHLKXQAAGOVID-UHFFFAOYSA-N 0.000 claims description 2
- QWYKNGNJCDCWLF-UHFFFAOYSA-N 7-[7-(2-chloroethoxy)-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC1CCCCC1)CCCCCN1CC2=CC(OCCCl)=C(OC)C=C2CC1 QWYKNGNJCDCWLF-UHFFFAOYSA-N 0.000 claims description 2
- FSXYFNIZWAGZKI-UHFFFAOYSA-N 8-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyloctanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 FSXYFNIZWAGZKI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- LEPRSEYFDFHJBY-UHFFFAOYSA-N methyl 5-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanoate Chemical compound C1CC2=CC(OC)=C(OC)C=C2CN1CCCC(C(=O)OC)(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 LEPRSEYFDFHJBY-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 11
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- CJJFSFFAFAEWIN-UHFFFAOYSA-N 2-[4-(3,4-dimethoxyphenyl)-4-(4-methylphenyl)sulfanylbutyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCN1CC2=CC(OC)=C(OC)C=C2CC1 CJJFSFFAFAEWIN-UHFFFAOYSA-N 0.000 claims 1
- FUXGUCORRPMWFN-UHFFFAOYSA-N 2-[6-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)sulfanyloctyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC(OC)=C(OC)C=C2CN1CCCCCC(CC)(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 FUXGUCORRPMWFN-UHFFFAOYSA-N 0.000 claims 1
- CCOVJCDBGJBWIV-UHFFFAOYSA-N 5-(6,7-dihydroxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCN1C(C)C2=CC(O)=C(O)C=C2CC1 CCOVJCDBGJBWIV-UHFFFAOYSA-N 0.000 claims 1
- OIULUAJKHYDICR-UHFFFAOYSA-N 7-[7-[tert-butyl(dimethyl)silyl]oxy-6-methoxy-1-(4-methylphenyl)sulfanyl-3,4-dihydro-1h-isoquinolin-2-yl]-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)CCCCCN1C(SC=2C=CC(C)=CC=2)C2=CC(O[Si](C)(C)C(C)(C)C)=C(OC)C=C2CC1 OIULUAJKHYDICR-UHFFFAOYSA-N 0.000 claims 1
- KHJORBJRUKOIEP-UHFFFAOYSA-N C1C2=CC=CC=C2C(C)=CN1CCCC(C#N)SC1=CC=C(C)C=C1 Chemical compound C1C2=CC=CC=C2C(C)=CN1CCCC(C#N)SC1=CC=C(C)C=C1 KHJORBJRUKOIEP-UHFFFAOYSA-N 0.000 claims 1
- YZYKGLASLCIMIN-UHFFFAOYSA-N [6-[7-(3,4-dimethoxyphenyl)-7-(4-methylphenyl)sulfanylheptyl]-2-(hydroxymethyl)-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-2-yl]methanol Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC(CO)(CO)O3)=C3C=C2CC1 YZYKGLASLCIMIN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 27
- 239000002246 antineoplastic agent Substances 0.000 abstract description 18
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 161
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 138
- 238000007912 intraperitoneal administration Methods 0.000 description 137
- 239000000047 product Substances 0.000 description 136
- 239000000243 solution Substances 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 105
- 239000000460 chlorine Substances 0.000 description 100
- 239000003921 oil Substances 0.000 description 100
- 235000019198 oils Nutrition 0.000 description 100
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 92
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- 239000000203 mixture Substances 0.000 description 80
- 229960004679 doxorubicin Drugs 0.000 description 72
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 69
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 68
- 238000000034 method Methods 0.000 description 65
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 57
- 239000011780 sodium chloride Substances 0.000 description 57
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 56
- 229960004528 vincristine Drugs 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 42
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 41
- 239000002904 solvent Substances 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
- 239000000902 placebo Substances 0.000 description 38
- 229940068196 placebo Drugs 0.000 description 38
- 239000007787 solid Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 19
- 238000001990 intravenous administration Methods 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 19
- 239000012230 colorless oil Substances 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- SHOWAGCIRTUYNA-UHFFFAOYSA-N 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydron;chloride Chemical compound [Cl-].C1C[NH2+]CC2=C1C=C(OC)C(OC)=C2 SHOWAGCIRTUYNA-UHFFFAOYSA-N 0.000 description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 239000012312 sodium hydride Substances 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- 239000003039 volatile agent Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- JCDCVCWOZFTTKJ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylacetonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)SC1=CC=C(C)C=C1 JCDCVCWOZFTTKJ-UHFFFAOYSA-N 0.000 description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 7
- 241000400611 Eucalyptus deanei Species 0.000 description 7
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 7
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- 229950008548 bisantrene Drugs 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000002024 ethyl acetate extract Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 7
- 239000000391 magnesium silicate Substances 0.000 description 7
- 229910052919 magnesium silicate Inorganic materials 0.000 description 7
- 235000019792 magnesium silicate Nutrition 0.000 description 7
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 6
- NNZRCFWPULYWHI-UHFFFAOYSA-N 7-chloro-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCCl)(C#N)SC1=CC=C(C)C=C1 NNZRCFWPULYWHI-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 6
- JBIOUFUTXZSWFB-UHFFFAOYSA-N 1,2-dimethoxy-4-[(4-methylphenyl)sulfanylmethyl]benzene Chemical compound C1=C(OC)C(OC)=CC=C1CSC1=CC=C(C)C=C1 JBIOUFUTXZSWFB-UHFFFAOYSA-N 0.000 description 5
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000002250 progressing effect Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- KKVZONPEMODBBG-UHFFFAOYSA-N (1-hydroxydodecane-1,1-diyl)bis(phosphonic acid) Chemical compound CCCCCCCCCCCC(O)(P(O)(O)=O)P(O)(O)=O KKVZONPEMODBBG-UHFFFAOYSA-N 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 4
- ZXNMIUJDTOMBPV-UHFFFAOYSA-N 2-chloroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCl)C=C1 ZXNMIUJDTOMBPV-UHFFFAOYSA-N 0.000 description 4
- RRBLNRINCRHDDH-UHFFFAOYSA-N 4-[6-bromo-1-(4-methylphenyl)sulfanylhexyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCBr)SC1=CC=C(C)C=C1 RRBLNRINCRHDDH-UHFFFAOYSA-N 0.000 description 4
- YDHOKAAOXWSQGH-UHFFFAOYSA-N 5-chloro-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCl)(C#N)SC1=CC=C(C)C=C1 YDHOKAAOXWSQGH-UHFFFAOYSA-N 0.000 description 4
- QAFDCJFBFFHATB-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-isoindol-5-ol Chemical compound C1=C(O)C(OC)=CC2=C1CNC2 QAFDCJFBFFHATB-UHFFFAOYSA-N 0.000 description 4
- WSUKMVDWBKJWLG-UHFFFAOYSA-N 7-amino-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCN)(C#N)SC1=CC=C(C)C=C1 WSUKMVDWBKJWLG-UHFFFAOYSA-N 0.000 description 4
- MHTLPFVHBVOGMZ-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol Chemical compound C1NCCC2=C1C=C(OC)C(O)=C2 MHTLPFVHBVOGMZ-UHFFFAOYSA-N 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- BIXLPTOONIGYAA-UHFFFAOYSA-N 1,2-bis(chloromethyl)-3,4-dimethoxybenzene Chemical compound COC1=CC=C(CCl)C(CCl)=C1OC BIXLPTOONIGYAA-UHFFFAOYSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- XLQDVTFUDWBBLS-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-iodo-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCI)(C#N)SC1=CC=C(C)C=C1 XLQDVTFUDWBBLS-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- ZIFOKFCCFUXYCZ-UHFFFAOYSA-N 4-[6-bromo-1-(4-methylphenyl)sulfanylheptyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCC(C)Br)SC1=CC=C(C)C=C1 ZIFOKFCCFUXYCZ-UHFFFAOYSA-N 0.000 description 3
- WMIINIMCTOCKNL-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydro-1h-isoindole Chemical compound C1=C(OC)C(OC)=CC2=C1CNC2 WMIINIMCTOCKNL-UHFFFAOYSA-N 0.000 description 3
- BTTKHQRLWUMJAR-UHFFFAOYSA-N 7-chloro-2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCCl)(C#N)SC1CCCCC1 BTTKHQRLWUMJAR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 206010048723 Multiple-drug resistance Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- NYJKGTUASGUHBQ-UHFFFAOYSA-N (7-bromo-1-phenylheptyl)sulfanylbenzene Chemical compound C=1C=CC=CC=1C(CCCCCCBr)SC1=CC=CC=C1 NYJKGTUASGUHBQ-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DZOBDJOLNPRDRV-UHFFFAOYSA-N 1,2-bis(bromomethyl)-4,5-dichlorobenzene Chemical compound ClC1=CC(CBr)=C(CBr)C=C1Cl DZOBDJOLNPRDRV-UHFFFAOYSA-N 0.000 description 2
- AKEIFADMFZIKLX-UHFFFAOYSA-N 1,2-bis(chloromethyl)-4-methoxy-5-phenylmethoxybenzene Chemical compound COC1=CC(CCl)=C(CCl)C=C1OCC1=CC=CC=C1 AKEIFADMFZIKLX-UHFFFAOYSA-N 0.000 description 2
- SMPZQAXDBHSPQL-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6-(3,4-dimethoxyphenyl)-6-(4-methylphenyl)sulfanyloctan-1-one Chemical compound C1CC2=CC(OC)=C(OC)C=C2CN1C(=O)CCCCC(CC)(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 SMPZQAXDBHSPQL-UHFFFAOYSA-N 0.000 description 2
- GNLGDVYFKYTCPB-UHFFFAOYSA-N 1-[6-bromo-1-(2-methylphenyl)sulfanylhexyl]-4-(trifluoromethoxy)benzene Chemical compound CC1=CC=CC=C1SC(CCCCCBr)C1=CC=C(OC(F)(F)F)C=C1 GNLGDVYFKYTCPB-UHFFFAOYSA-N 0.000 description 2
- MWNZEITVYOKWRM-UHFFFAOYSA-N 1-[6-bromo-1-(4-fluorophenyl)hexyl]sulfanyl-4-methylbenzene Chemical compound C1=CC(C)=CC=C1SC(CCCCCBr)C1=CC=C(F)C=C1 MWNZEITVYOKWRM-UHFFFAOYSA-N 0.000 description 2
- PHHNNDKXQVKJEP-UHFFFAOYSA-N 1-bromo-5-chloropentane Chemical compound ClCCCCCBr PHHNNDKXQVKJEP-UHFFFAOYSA-N 0.000 description 2
- IBRKLUSXDYATLG-UHFFFAOYSA-N 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Chemical compound OC1=C(O)C=C2C(C)NCCC2=C1 IBRKLUSXDYATLG-UHFFFAOYSA-N 0.000 description 2
- MELCGMWXQYRINR-UHFFFAOYSA-N 1-methyl-4-[[4-(trifluoromethoxy)phenyl]methylsulfanyl]benzene Chemical compound C1=CC(C)=CC=C1SCC1=CC=C(OC(F)(F)F)C=C1 MELCGMWXQYRINR-UHFFFAOYSA-N 0.000 description 2
- BFGAPGSBVWPIMS-UHFFFAOYSA-N 13-bromo-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyltridecanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCCCCCCCBr)(C#N)SC1=CC=C(C)C=C1 BFGAPGSBVWPIMS-UHFFFAOYSA-N 0.000 description 2
- RFAXQHFSOPOZBA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(1,3-dioxoisoindol-2-yl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1C(=O)C2=CC=CC=C2C1=O RFAXQHFSOPOZBA-UHFFFAOYSA-N 0.000 description 2
- UCPKKHBZTKCRSR-UHFFFAOYSA-N 2-[7-[3-(2-chloroethoxy)-4-methoxyphenyl]-7-(4-methylphenyl)sulfanylheptyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(OCCCl)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 UCPKKHBZTKCRSR-UHFFFAOYSA-N 0.000 description 2
- XPIRHIKVYOEMJV-UHFFFAOYSA-N 2-benzyl-5-methoxy-6-phenylmethoxy-1,3-dihydroisoindole Chemical compound C1C=2C=C(OCC=3C=CC=CC=3)C(OC)=CC=2CN1CC1=CC=CC=C1 XPIRHIKVYOEMJV-UHFFFAOYSA-N 0.000 description 2
- AFSNCSXRLHCEKN-UHFFFAOYSA-N 2-chloro-2-(3,4-dimethoxyphenyl)acetonitrile Chemical compound COC1=CC=C(C(Cl)C#N)C=C1OC AFSNCSXRLHCEKN-UHFFFAOYSA-N 0.000 description 2
- QYZRLGMJZQTJAV-UHFFFAOYSA-N 2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)acetonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)SC1CCCCC1 QYZRLGMJZQTJAV-UHFFFAOYSA-N 0.000 description 2
- ZPKLEIJQNBRWMF-UHFFFAOYSA-N 3-[2-cyano-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylethyl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CC1=CC=CC(C(O)=O)=C1 ZPKLEIJQNBRWMF-UHFFFAOYSA-N 0.000 description 2
- DXKGCTLFVFOMBU-UHFFFAOYSA-N 4-[4-chloro-1-(4-methylphenyl)sulfanylbutyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCl)SC1=CC=C(C)C=C1 DXKGCTLFVFOMBU-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- NLKKJTURYWKDCH-UHFFFAOYSA-N 5-(6,7-dihydroxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCN1C(C)C2=CC(O)=C(O)C=C2CC1 NLKKJTURYWKDCH-UHFFFAOYSA-N 0.000 description 2
- WHKRHBLAJFYZKF-UHFFFAOYSA-N 5-(hydroxymethyl)-2-methoxyphenol Chemical compound COC1=CC=C(CO)C=C1O WHKRHBLAJFYZKF-UHFFFAOYSA-N 0.000 description 2
- GYCIOJJPAOEEHA-UHFFFAOYSA-N 5-[(4-methylphenyl)sulfanylmethyl]-1,3-benzodioxole Chemical compound C1=CC(C)=CC=C1SCC1=CC=C(OCO2)C2=C1 GYCIOJJPAOEEHA-UHFFFAOYSA-N 0.000 description 2
- OQGVQXMDGTUCOB-UHFFFAOYSA-N 5-[[2-[2-[(3-hydroxy-4-methoxyphenyl)methyl]-4-methylphenyl]sulfanyl-5-methylphenyl]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1CC1=CC(C)=CC=C1SC1=CC=C(C)C=C1CC1=CC=C(OC)C(O)=C1 OQGVQXMDGTUCOB-UHFFFAOYSA-N 0.000 description 2
- LQXITULNEVIDQF-UHFFFAOYSA-N 5-chloro-2-(3,4-dimethoxyphenyl)-4-methyl-2-(4-methylphenyl)sulfanylpentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(C)CCl)(C#N)SC1=CC=C(C)C=C1 LQXITULNEVIDQF-UHFFFAOYSA-N 0.000 description 2
- DULPDLSRFKJSQD-UHFFFAOYSA-N 6-benzylsulfanyl-1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6-(3,4-dimethoxyphenyl)hexan-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(SCC=1C=CC=CC=1)CCCCC(=O)N1CC2=CC(OC)=C(OC)C=C2CC1 DULPDLSRFKJSQD-UHFFFAOYSA-N 0.000 description 2
- DKGFTMOPFVNAKN-UHFFFAOYSA-N 6-chloro-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylhexanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCl)(C#N)SC1=CC=C(C)C=C1 DKGFTMOPFVNAKN-UHFFFAOYSA-N 0.000 description 2
- YYTAYINRPUJPNH-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(OC)=CC=C21 YYTAYINRPUJPNH-UHFFFAOYSA-N 0.000 description 2
- MGWYVHPDHWXCNS-UHFFFAOYSA-N 6-methoxy-7-phenylmethoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.COC1=CC=2CCNCC=2C=C1OCC1=CC=CC=C1 MGWYVHPDHWXCNS-UHFFFAOYSA-N 0.000 description 2
- ZKIVQYUSWDJIBT-UHFFFAOYSA-N 7-amino-2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCN)(C#N)SC1CCCCC1 ZKIVQYUSWDJIBT-UHFFFAOYSA-N 0.000 description 2
- FJRXDYMKHVEMIC-UHFFFAOYSA-N 7-bromo-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyldecanenitrile Chemical compound C=1C=C(OC)C(OC)=CC=1C(CCCCC(Br)CCC)(C#N)SC1=CC=C(C)C=C1 FJRXDYMKHVEMIC-UHFFFAOYSA-N 0.000 description 2
- KQUPBKDZMPDBMO-UHFFFAOYSA-N 7-chloro-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanyloctanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCC(C)Cl)(C#N)SC1=CC=C(C)C=C1 KQUPBKDZMPDBMO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
- 208000008342 Leukemia P388 Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- WSCRUXVCUXHCOW-UHFFFAOYSA-N [4,5-dichloro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC(Cl)=C(Cl)C=C1CO WSCRUXVCUXHCOW-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 101150053100 cls1 gene Proteins 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VOYUDLQQSIGHLU-UHFFFAOYSA-N tert-butyl 7-[tert-butyl(dimethyl)silyl]oxy-6-methoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC2=C1C=C(OC)C(O[Si](C)(C)C(C)(C)C)=C2 VOYUDLQQSIGHLU-UHFFFAOYSA-N 0.000 description 2
- XRCGJEVLBYMDMK-UHFFFAOYSA-N tert-butyl-[(6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy]-dimethylsilane Chemical compound C1CNCC2=C1C=C(OC)C(O[Si](C)(C)C(C)(C)C)=C2 XRCGJEVLBYMDMK-UHFFFAOYSA-N 0.000 description 2
- PBVZCSNLZISYLK-UHFFFAOYSA-N tert-butyl-[[6-[tert-butyl(dimethyl)silyl]oxy-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy]-dimethylsilane Chemical compound C1CNCC2=C1C=C(O[Si](C)(C)C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C2 PBVZCSNLZISYLK-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- SIBVHGAPHVRHMJ-UHFFFAOYSA-N 1,11-dibromoundecane Chemical compound BrCCCCCCCCCCCBr SIBVHGAPHVRHMJ-UHFFFAOYSA-N 0.000 description 1
- LBDAQUYUIYKBKJ-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrobromide Chemical compound Br.C1CNCC2=C1C=C(O)C(O)=C2 LBDAQUYUIYKBKJ-UHFFFAOYSA-N 0.000 description 1
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 1
- ZVLUYVVSBSHOMP-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6-(3,4-dimethoxyphenyl)-6-hydroxyoctan-1-one Chemical compound C1CC2=CC(OC)=C(OC)C=C2CN1C(=O)CCCCC(O)(CC)C1=CC=C(OC)C(OC)=C1 ZVLUYVVSBSHOMP-UHFFFAOYSA-N 0.000 description 1
- LBMKFQMJURUPKC-UHFFFAOYSA-N 1-(chloromethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CCl)C=C1 LBMKFQMJURUPKC-UHFFFAOYSA-N 0.000 description 1
- VMPLLPIDRGXFTQ-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CC[NH2+]1 VMPLLPIDRGXFTQ-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XLKLYJMIRXCQEJ-UHFFFAOYSA-N 1-[bromo(phenyl)methyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1C(Br)C1=CC=CC=C1 XLKLYJMIRXCQEJ-UHFFFAOYSA-N 0.000 description 1
- ZKDOQFPDSUOLGF-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylpropane Chemical compound ClCC(C)CBr ZKDOQFPDSUOLGF-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- MNELLQACUSWKSP-UHFFFAOYSA-N 1-methoxy-2-phenylmethoxybenzene Chemical compound COC1=CC=CC=C1OCC1=CC=CC=C1 MNELLQACUSWKSP-UHFFFAOYSA-N 0.000 description 1
- TZOVOULUMXXLOJ-UHFFFAOYSA-N 1-methyl-4-[(4-methylphenyl)disulfanyl]benzene Chemical compound C1=CC(C)=CC=C1SSC1=CC=C(C)C=C1 TZOVOULUMXXLOJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GQGAUUPJUVHULU-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-2-pyridin-2-ylsulfanylacetonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)SC1=CC=CC=N1 GQGAUUPJUVHULU-UHFFFAOYSA-N 0.000 description 1
- UJJKCMUVGUGTQF-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(5-hydroxy-6-methoxy-1,3-dihydroisoindol-2-yl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1C=2C=C(O)C(OC)=CC=2CN1CCCCCC(C=1C=C(OC)C(OC)=CC=1)(C#N)SC1=CC=C(C)C=C1 UJJKCMUVGUGTQF-UHFFFAOYSA-N 0.000 description 1
- KFPYSCPYPALCDC-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-[5-(2-imidazol-1-ylethoxy)-6-methoxy-1,3-dihydroisoindol-2-yl]-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(OCCN3C=NC=C3)=C(OC)C=C2C1 KFPYSCPYPALCDC-UHFFFAOYSA-N 0.000 description 1
- ASLSUMISAQDOOB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1OC ASLSUMISAQDOOB-UHFFFAOYSA-N 0.000 description 1
- JVIBCEVSLTYPFB-UHFFFAOYSA-N 2-[7-(3,4-dimethoxyphenyl)-7-(4-methylphenyl)sulfanylheptyl]-5,6-dimethoxy-1,3-dihydroisoindole Chemical compound C1=C(OC)C(OC)=CC=C1C(SC=1C=CC(C)=CC=1)CCCCCCN1CC2=CC(OC)=C(OC)C=C2C1 JVIBCEVSLTYPFB-UHFFFAOYSA-N 0.000 description 1
- CIEOWICVMFPKSB-UHFFFAOYSA-N 2-[7-[3-(2-imidazol-1-ylethoxy)-4-methoxyphenyl]-7-(4-methylphenyl)sulfanylheptyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline;dihydrochloride Chemical compound Cl.Cl.COC1=CC=C(C(CCCCCCN2CC3=CC(OC)=C(OC)C=C3CC2)SC=2C=CC(C)=CC=2)C=C1OCCN1C=CN=C1 CIEOWICVMFPKSB-UHFFFAOYSA-N 0.000 description 1
- NXVKGPNPQFGJQX-UHFFFAOYSA-N 2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)-7-(1,3-dioxoisoindol-2-yl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC1CCCCC1)CCCCCN1C(=O)C2=CC=CC=C2C1=O NXVKGPNPQFGJQX-UHFFFAOYSA-N 0.000 description 1
- OWGYKOSLGHUKQB-UHFFFAOYSA-N 2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)-7-(7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)heptanenitrile Chemical compound C1C=2C=C(O)C(OC)=CC=2CCN1CCCCCC(C=1C=C(OC)C(OC)=CC=1)(C#N)SC1CCCCC1 OWGYKOSLGHUKQB-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- FTPAHNNMUYOHOB-UHFFFAOYSA-N 3-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CBr)=C1 FTPAHNNMUYOHOB-UHFFFAOYSA-N 0.000 description 1
- CGWOEOXQHIMZEQ-UHFFFAOYSA-N 3-[1-[[4-(2-phenylquinolin-3-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=CC2=CC=CC=C2N=C1C1=CC=CC=C1 CGWOEOXQHIMZEQ-UHFFFAOYSA-N 0.000 description 1
- JZIWEQLMGHTKOW-UHFFFAOYSA-N 3-[3-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)phenyl]-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpropanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CC1=CC=CC(N2CC3=CC(OC)=C(OC)C=C3CC2)=C1 JZIWEQLMGHTKOW-UHFFFAOYSA-N 0.000 description 1
- MYLSBSPLUYUCDF-UHFFFAOYSA-N 3-[3-(chloromethyl)phenyl]-2-(2,3-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpropanenitrile Chemical compound COC1=CC=CC(C(CC=2C=C(CCl)C=CC=2)(SC=2C=CC(C)=CC=2)C#N)=C1OC MYLSBSPLUYUCDF-UHFFFAOYSA-N 0.000 description 1
- FXEASGQYZVFXMI-UHFFFAOYSA-N 3-[3-(chloromethyl)phenyl]-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylpropanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CC1=CC=CC(CCl)=C1 FXEASGQYZVFXMI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FDOQKGWUMUEJLX-UHFFFAOYSA-N 4,5-dichlorophthalic acid Chemical compound OC(=O)C1=CC(Cl)=C(Cl)C=C1C(O)=O FDOQKGWUMUEJLX-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- IDBMZPVJVQXCIS-UHFFFAOYSA-N 4-chloro-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylbutanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCl)(C#N)SC1=CC=C(C)C=C1 IDBMZPVJVQXCIS-UHFFFAOYSA-N 0.000 description 1
- DWSUJONSJJTODA-UHFFFAOYSA-N 5-(chloromethyl)-1,3-benzodioxole Chemical compound ClCC1=CC=C2OCOC2=C1 DWSUJONSJJTODA-UHFFFAOYSA-N 0.000 description 1
- BIELQIRYUIRTGZ-UHFFFAOYSA-N 5-bromopentyl-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)CCCCCBr BIELQIRYUIRTGZ-UHFFFAOYSA-N 0.000 description 1
- PHKCANZMBIZCFV-UHFFFAOYSA-N 6-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylhexanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCN1CC2=CC(OC)=C(OC)C=C2CC1 PHKCANZMBIZCFV-UHFFFAOYSA-N 0.000 description 1
- JYMUWKRSBQHZRB-UHFFFAOYSA-N 6-cyclohexylsulfanyl-1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6-(3,4-dimethoxyphenyl)hexan-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(SC1CCCCC1)CCCCC(=O)N1CC2=CC(OC)=C(OC)C=C2CC1 JYMUWKRSBQHZRB-UHFFFAOYSA-N 0.000 description 1
- IMANTYHQRXVHNW-UHFFFAOYSA-N 6-tert-butylsulfanyl-1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-6-(3,4-dimethoxyphenyl)hexan-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(SC(C)(C)C)CCCCC(=O)N1CC2=CC(OC)=C(OC)C=C2CC1 IMANTYHQRXVHNW-UHFFFAOYSA-N 0.000 description 1
- BOSMTTOBTZIOLM-UHFFFAOYSA-N 7-(5,6-dimethoxy-1,3-dihydroisoindol-2-yl)heptanenitrile hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC2=C1CN(CCCCCCC#N)C2 BOSMTTOBTZIOLM-UHFFFAOYSA-N 0.000 description 1
- HVCQOFNIKZRLKI-UHFFFAOYSA-N 7-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2-(3,4-dimethoxyphenyl)-2-pyridin-2-ylsulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1N=CC=CC=1)CCCCCN1CC2=CC(OC)=C(OC)C=C2CC1 HVCQOFNIKZRLKI-UHFFFAOYSA-N 0.000 description 1
- FMUNXGPCDSYUIL-UHFFFAOYSA-N 7-[7-[tert-butyl(dimethyl)silyl]oxy-6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(C#N)(SC=1C=CC(C)=CC=1)CCCCCN1CC2=CC(O[Si](C)(C)C(C)(C)C)=C(OC)C=C2CC1 FMUNXGPCDSYUIL-UHFFFAOYSA-N 0.000 description 1
- MBTIYDDPDAHADF-UHFFFAOYSA-N 7-bromo-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCBr)(C#N)SC1=CC=C(C)C=C1 MBTIYDDPDAHADF-UHFFFAOYSA-N 0.000 description 1
- FHJYUEYURFYGJJ-UHFFFAOYSA-N 7-bromo-2-(3,4-dimethoxyphenyl)-2-pyridin-2-ylsulfanylheptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCBr)(C#N)SC1=CC=CC=N1 FHJYUEYURFYGJJ-UHFFFAOYSA-N 0.000 description 1
- GWLQWGLAURBEOT-UHFFFAOYSA-N 7-bromo-2-cyclohexylsulfanyl-2-(3,4-dimethoxyphenyl)heptanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CCCCCBr)(C#N)SC1CCCCC1 GWLQWGLAURBEOT-UHFFFAOYSA-N 0.000 description 1
- FQNJTXKHAXATEL-UHFFFAOYSA-N 7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinoline-2-carboxylic acid Chemical compound C1CN(C(O)=O)CC2=C1C=C(OC)C(O)=C2 FQNJTXKHAXATEL-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BLUKFTKWBZDSPZ-UHFFFAOYSA-N CCCCCCC#N.C1=CC=C2CNC=CC2=C1 Chemical compound CCCCCCC#N.C1=CC=C2CNC=CC2=C1 BLUKFTKWBZDSPZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 229910003204 NH2 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 101100434170 Oryza sativa subsp. japonica ACR2.1 gene Proteins 0.000 description 1
- 101100434171 Oryza sativa subsp. japonica ACR2.2 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- UODUOSSPXZISSR-UHFFFAOYSA-N [5-[7-bromo-1-(4-methylphenyl)sulfanylheptyl]-2-methoxyphenoxy]-butan-2-yl-dimethylsilane Chemical compound C1=C(OC)C(O[Si](C)(C)C(C)CC)=CC(C(CCCCCCBr)SC=2C=CC(C)=CC=2)=C1 UODUOSSPXZISSR-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PWAXUOGZOSVGBO-UHFFFAOYSA-N adipoyl chloride Chemical compound ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- GOBKARNYNSWQFZ-UHFFFAOYSA-N anhalinine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2OC GOBKARNYNSWQFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- LKMCJXXOBRCATQ-UHFFFAOYSA-N benzylsulfanylbenzene Chemical compound C=1C=CC=CC=1CSC1=CC=CC=C1 LKMCJXXOBRCATQ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- SISAYUDTHCIGLM-UHFFFAOYSA-N bromine dioxide Inorganic materials O=Br=O SISAYUDTHCIGLM-UHFFFAOYSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- OSVXSBDYLRYLIG-UHFFFAOYSA-N chlorine dioxide Inorganic materials O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- CMKBCTPCXZNQKX-UHFFFAOYSA-N cyclohexanethiol Chemical compound SC1CCCCC1 CMKBCTPCXZNQKX-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PFZYFZRUPFUEOB-UHFFFAOYSA-N diethyl 2,2-dibromopropanedioate Chemical compound CCOC(=O)C(Br)(Br)C(=O)OCC PFZYFZRUPFUEOB-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- IIGAHJNOKFXZDI-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)-7-hydroxy-2-(2-methylphenyl)sulfanylheptanoate Chemical compound C=1C=C(OC)C(OC)=CC=1C(CCCCCO)(C(=O)OC)SC1=CC=CC=C1C IIGAHJNOKFXZDI-UHFFFAOYSA-N 0.000 description 1
- DILOFCBIBDMHAY-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C(OC)=C1 DILOFCBIBDMHAY-UHFFFAOYSA-N 0.000 description 1
- IFXBHTKIVJMGJJ-UHFFFAOYSA-N methyl 7-(5,6-dimethoxy-1,3-dihydroisoindol-2-yl)-2-(3,4-dimethoxyphenyl)-2-(4-methylphenyl)sulfanylheptanoate Chemical compound C1C2=CC(OC)=C(OC)C=C2CN1CCCCCC(C(=O)OC)(C=1C=C(OC)C(OC)=CC=1)SC1=CC=C(C)C=C1 IFXBHTKIVJMGJJ-UHFFFAOYSA-N 0.000 description 1
- PXBFNVYBNLNXKV-UHFFFAOYSA-N methyl 7-[tert-butyl(dimethyl)silyl]oxy-2-(3,4-dimethoxyphenyl)heptanoate Chemical compound CC(C)(C)[Si](C)(C)OCCCCCC(C(=O)OC)C1=CC=C(OC)C(OC)=C1 PXBFNVYBNLNXKV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- JHLDJOBIUVJSTG-UHFFFAOYSA-N tdiq Chemical compound C1CNCC2=C1C=C1OCOC1=C2 JHLDJOBIUVJSTG-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- NXGLYAKMESSSPJ-UHFFFAOYSA-N tert-butyl 7-hydroxy-6-methoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC2=C1C=C(OC)C(O)=C2 NXGLYAKMESSSPJ-UHFFFAOYSA-N 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/01—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton
- C07C323/02—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/07—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention describes various bicyclic amines that are effective in resensitizing multiple drug resistant cells to chemotherapeutic agents such as doxorubicin, vincristine and bisantrene.
- chemotherapeutic agents such as doxorubicin, vincristine and bisantrene.
- This resensitization has the effect of reducing the amount of chemotherapeutic agent necessary to kill those cells.
- this potentiation of activity of the chemotherapeutic agent with the compounds of this invention makes it possible to treat multi-drug resistant tumors in animals.
- An object of this invention is to provide a method for increasing the sensitivity of multi-drug resistant cells by the use of compounds of this invention.
- An additional object of this invention is to provide a method for treating tumors that are either intrinsically or extrinsically multi-drug resistant in warm blooded animals by the administration of a therapeutically effective dose of a compound of this invention prior to, concurrent or after the administration of a therapeutically effective dose of an antitumor chemotherapeutic agent.
- Resistance of tumor cells to chemotherapeutic drugs is an important problem in the clinical management of cancer.
- One type of resistance is characterized by the cross resistance to a wide variety of chemotherapeutic agents with no major structural similarities or similar modes of action. This phenomenon is termed multiple drug resistance.
- the evidence suggests that this form of resistance is due to the presence in tumor cells of a 170 kD trans-membrane protein that is termed P-glycoprotein. It is thought that resistance is conferred by the ability of P-glycoprotein to actively transport chemotherapeutic agents out of the cells and thereby lower the intracellular concentrations of such drugs to non-toxic levels. Clinically this translates into a reduction of the therapeutic index of such drugs to an ineffective level.
- MDR1 mRNA levels are elevated in untreated, intrinsically drug resistant tumors including those derived from the colon, kidney, adrenal gland, liver and pancreas as well as some cancers at relapse after chemotherapy including breast cancer, neuroblastoma, ALL and nodular poorly differentiated lymphoma.
- Chemotherapeutic agents in clinical use to which multi-drug resistance has been observed include doxorubicin, vinblastine, vincristine, taxol, duanomycin, etopiside, teniposide and actinomycin D.
- the present invention describes various bicyclic amines that are effective in resensitizing multiple drug resistant cells to chemotherapeutic agents such as doxorubicin, vincristine and bisantrene.
- chemotherapeutic agents such as doxorubicin, vincristine and bisantrene.
- This resensitization has the effect of reducing the amount of chemotherapeutic agent neccessary to kill those cells.
- this potentiation of activity of the chemotherapeutic agent with the compounds of this invention makes it possible to treat multi-drug resistant tumors in warm blooded animals.
- An object of this invention is provide a method for increasing the sensitivity of multi-drug resistant cells by the use of compounds in this invention.
- An additional object of this invention is to provide a method for treating tumors that are either intrinsically or extrinsically multi-drug resistant in warm blooded animals by the administration of a therapeutically effective dose of a compound of this invention prior to, concurrent or after the administration of a therapeutically effective dose of an antitumor chemotherapeutic agent.
- R 2 is H, OH, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, NO 2 , OCF 3 , alkyl(C 1 -C 6 ), or N(R 12 ) 2 ;
- R 3 is H, OH, O-alkyl(C 1 -C 3 ), straight or branched
- O-alkyl(C 2 -C 5 )N(R 12 ) 2 , OSO 2 CF 3 , OCF 3 , or N(R 12 ) 2 ; or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H, OH, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, or alkyl ( C 1 -C 3 );
- R 5 is H, CN, CH 2 OH, CO 2 (C 1 -C 3 )alkyl, CH 2 NH 2 , CH 2 N(R 12 ) 2 or alkyl ( C 1 -C 3 );
- R 1 is straight or branched (C 1 -C 12 )alkyl, cycloalkyl (C 3 -C 7 ), bicycloalkyl (C 6 -C 10 ), tricycloalkyl(C 6 -C 10 ), a heterocycle or ##STR4##
- m is an integer 0-3,
- X is H, straight or branched (C 1 -C 4 )alkyl, I,
- A is straight or branched (C 2-C 12 )alkyl, ##STR5##
- B is ##STR6##
- R 6 is H, alkyl(C 1 -C 4 ), or
- R 9 is H, O-alkyl(C 1 -C 4 ), F, Br,
- R 10 is H, O-alkyl(C 1 -C 3 ), OH,
- OCF 3 OCH 2 -phenyl, NO 2 or N(R 12 ) 2 ;
- R 11 is H, O-alkyl (C 1 -C 4 ),
- R 12 is alkyl(C 1 -C 4 );
- R 2 is H, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, OCF 3 , or alkyl(C 1 -C 6 );
- R 3 is H, O-alkyl(C 1 -C 3 ), straight or branched
- OCH 2 CH 2 Cl O-alkyl(C 2 -C 5 )-heterocycle, OSO 2 CF 3 , or OCF 3 ;
- R 2 and R 3 taken together are methylenedioxy or ethylenedioxy
- R 4 is H, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, or alkyl(C 1 -C 6 );
- R 5 is H, CN, CH 2 OH, CO 2 (C 1 -C 3 )alkyl, or alkyl(C 1 -C 3 );
- R 1 is straight or branched (C 1 -C 12 )alkyl, cycloalkyl(C 3 -C 7 ), 70 bicycloalkyl(C 6 -C 10 ), tricycloalkyl (C 6 -C 10 ), a heterocycle or ##STR9##
- m is an integer 0-3,
- X is H, straight or branched(C 1 -C 4 )alkyl, I,
- A is straight or branched(C 2 -C 12 )alkyl, ##STR10##
- R 9 is H, O-alkyl(C 1 -C 4 ), F, Br,
- R 10 is H, O-alkyl(C 1 -C 3 ), OH,
- R 11 is H, O-alkyl(C 1 -C 4 ), OH,
- R 12 is alkyl(C 1 -C 4 ); and the pharmaceutically acceptable salts thereof.
- R 3 is H, O-alkyl(C 1 -C 3 ), OSi(t-C 4 H 9 ) (CH 3 ) 2 , alkyl(C 1 -C 6 ), OCH 2 CH 2 Cl, OCH 2 CH 2 -N-imidazole or OSO 2 CF 3 ; or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H, O-alkyl(C 1 -C 4 ), or alkyl(C 1 -C 6 );
- R 5 is H, CN, CH 2 OH, CO 2 (C 1 -C 3 )alkyl, or alkyl(C 1 -C 3 );
- R 1 is straight or branched (C 1 -C 12 )alkyl, cycloalkyl(C 3 -C 7 ), bicycloalkyl (C 6 -C 10 ), tricycloalkyl(C 6 -C 10 ), a heterocycle or ##STR14##
- m is an integer 0-3, X is H, straight or branched (C 1 -C 4 )alkyl;
- A is straight or branched (C2-C12)alkyl, ##STR15##
- R 9 is H or O-alkyl(C 1 -C 4 );
- R 10 is H, O-alkyl(C 1 -C 3 ), OH,
- R 11 is H, O-alkyl(C 1 -C 4 ), OH,
- R 12 is alkyl(C 1 -C 4 ); and the pharmaceutically acceptable salts thereof.
- R 3 is H, O-CH 3 , OSi(t-C 4 H 9 )(CH 3 ) 2 , OCH 2 CH 2 Cl, OCH 2 CH 2 -N-imidazole or OSO 2 CF 3; or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H or O-CH 3 ;
- R 5 is H, CN, CH 2 OH, CO 2 CH 3 , or alkyl(C 1 -C 3 );
- R 1 is straight or branched (C 4 -C 5 )alkyl, cycloalkyl(C 5 -C 6 ), adamantyl 2 -pyridyl or ##STR19##
- m is an integer 0-1;
- X is H, straight or branched (C 1 -C 4 ) alkyl;
- A is straight or branched (C 2 -C 12 )alkyl, ##STR20##
- R 9 is H or O-alkyl(C 1 -C 4 );
- R 10 is H, O-CH 3 , OH,
- R 11 is H, O-CH 3 , OH, Cl;
- R 12 is alkyl(C 1 -C 4 ); and the pharmaceutically acceptable salts thereof.
- a heterocycle is a 5-6 membered ring containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen atoms.
- Representative heterocycles are imidazole, pyrrole, 1,2,4-triazole, oxazole, isoxazole, furan, thiophene, pyridine, pyrimidine and thiazole.
- Such intermediate compounds include those of formula: ##STR23## wherein R 2 is H, OH, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, NO 2 , OCF 3 , alkyl(C 1 -C 6 ), or N(R 12 ) 2 ;
- R 3 is H, OH, O-alkyl(C 1 -C 3 ), straight or branched
- O-alkyl(C 2 -C 5 )N(R 12 ), OCF 3 , or N(R 12 ) 2 ; or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H, OH, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, or alkyl(C 1 -C 3 );
- R 5 is H, CN, CH 2 OH, CO 2 (C 12 -C 3 )alkyl or alkyl(C 1 -C 3 );
- R 1 is straight or branched (C 1 -C 12 ) alkyl, cycloalkyl (C 3 -C 7 ), bicycloalkyl (C 6 -C 10 ), tricycloalkyl (C 6 -C 10 ), ##STR24## m is an integer 0-3, X is H, straight or branched (C 1 -C 4 )alkyl, I,
- R 1 is a heterocycle with the proviso that the heterocycle cannot be ##STR25## where r is an integer 1-4; A is straight or branched (C 2 -C 12 )alkyl, ##STR26## W is Br, Cl, I, NH 2 , OSO 2 alkyl(C 1 -C 3 ), OSO 2 CF 3 ,
- R 12 is alkyl(C 1 -C 4 ); and the pharmaceutically acceptable salts thereof.
- a heterocycle is a 5-6 membered ring containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen atoms.
- Representative heterocycles are imidazole, pyrrole, 1,2,4-triazole, oxazole, isoxazole, furan, thiophene, pyridine, pyrimidine and thiazole.
- This invention is concerned with the use of the compounds of this invention with anticancer chemotherapeutic agents in the treatment of multi-drug resistant tumors and the treatment of cancer.
- the compounds of the present invention have the ability to resensitize multi-drug resistant cells to antitumor chemotherapeutic agents such as vincristine, doxrubicin, and bisantrene. Further it has been discovered that compounds of the present invention have the ability to potentiate the ability of antitumor therapeutic agents such as doxorubicin to reduce the tumor size in animals bearing mutli-drug resistant tumors. Due to these properties the compounds of the present invention are expected to have a major clinical use in the treatment of multi-drug resistant tumors.
- the compounds of this invention may be prepared according to one or more of the following reaction schemes: ##STR27##
- R 3 is H, OH, O-alkyl(C 1 -C 3 ), straight or branched
- OCF 3 O-alkyl(C 2 -C 5 ) -heterocycle, or
- O-alkyl (C 2 - 5 )N(R 12 ) 2 , or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H, OH, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, or alkyl (C 1 -C 3 );
- R 5 is H, CN, CO 2 (C 1 -C 3 )alkyl, alkyl(C 1 -C 3 ), CH 2 NH 2 , or CH 2 N (R 12 ) 2 ;
- R 1 is straight or branched (C 1 -C 12 )alkyl, cycloalkyl(C 3 -C 7 ), bicycloalkyl (C 6 -C 10 ), tricycloalkyl(C 6 -C 10 ), a heterocycle or ##STR29##
- m is an integer 0-3,
- X is H, straight or branched (C 1 -C 4 )alkyl, I,
- A is straight or branched (C 2 -C 12 )alkyl, ##STR30##
- R 9 is H, O-alkyl(C 1 -C 4 ), F, Br,
- R 10 is H, O-alkyl(C 1 -C 3 ), OH, S-alkyl(C 1 -C 4 ),
- O-alkyl (C 2 -C 5 ) -heterocycle OSO 2 CF 3 , OCF 3 ,
- R 11 is H, O-alkyl(C 1 -C 4 ),
- R 12 is alkyl (C 1 -C 4 );
- the arylchloroacetonitrile 3, may be prepared from the aryl aldehyde, 1, via Z as described in U.S. Pat. No. 4,833,162.
- the intermediate 4 may be prepared from 3, by reaction of 3 with R 1 SH, wherein R 1 is as defined hereinabove, and a base in polar solvents such as acetonitrile at elevated temperatures. Deprotonation of 4 with a strong base such as sodium hydride in an aprotic solvent such as dimethylsulfoxide and reacting with X--A--Y, wherein A is as defined hereinabove and X and Y are independently chlorine, bromine or iodine, affords intermediate 5.
- Reaction of 5 with HB, wherein B is as defined hereinabove, in a polar solvent such as N,N-dimethylformamide and a tertiary amine or alkali carbonate such as potassium carbonate at elevated temperatures affords 6.
- intermediate 4 can be prepared by treatment of compound 7 with a strong base such as lithium hexamethyldisilazide in an ethereal solvent such as tetrahydrofuran and then with a disulfide, R 1 SSR 1 , wherein R 1 is as defined hereinabove.
- R 3 is H, O-alkyl(C 1 -C 3 ), F, Br, Cl, I, or alkyl (C 1 -C 6 ); or R 2 and R 3 taken together are methylenedioxy or ethylenedioxy;
- R 4 is H, O-alkyl(C 1 -C 4 ), F, Br, Cl, I, or alkyl(C 1 -C 3 );
- R 5 is H
- R 1 is straight or branched (C 1 -C 12 ) alkyl, cycloalkyl(C 3 -C 7 ), bicycloalkyl(C 6 -C 10 ), a heterocycle or ##STR36##
- m is an integer 0-3,
- X is H, straight or branched (C 1 -C 4 )alkyl, I,
- alkyl C 1 -C 4
- O-alkyl C 1 -C 4
- R 9 is H, O-alkyl(C 1 -C 4 ), F, Br,
- R 10 is H, O-alkyl(C 1 -C 3 ), OH, S-alkyl(C 1 -C 4 ),
- R 11 is H, O-alkyl(C 1 -C 4 ),
- R 12 is alkyl(C 1 -C 4 );
- acylation of compound 12 with compound 13 with a Lewis acid such as aluminum chloride in a solvent such as methylene chloride affords compound 14 after saponification with a base such as sodium hydroxide in alcohol water mixtures.
- a base such as sodium hydroxide in alcohol water mixtures.
- Acylation of compound 14 with BH, wherein B is as defined hereinabove by activation of 14 with reagents such as diethylcyanophosphonate in solvents such as N,N-dimethylformamide in the presence of tertiary amine bases affords compound 15.
- Reduction of compound 15 with reagents such as sodium borohydride in alcoholic solvents affords compound 16.
- a subpopulation of human ovarian carcinoma cells (OVCAR-3, also known as HTB-161) is obtained by selecting cells for high expression of the B72.3 antigen. Such cells are sorted by a fluorescent activated cell sorter (FACS; Becton Dickinson Model 440).
- FACS Fluorescence activated cell sorter
- a clone (S1) from this population is isolated and then subjected to step-wise increasing amounts of bisantrene over a period of 12-16 weeks.
- the most resistant cell line, designated S1-B1-20 denotes the S1 clone, the first independently-isolated bisantrene-selected cell line (B1), and the maintenance concentration in micromolar (20 ⁇ M).
- the bisantrene-selected cells used in this study are chronically maintained in 20 ⁇ M drug (the limit of solubility of bisantrene).
- Cells prepared by trypsinization, are plated at 20,000 cells/well in media with and without bisantrene. Then, test agents at varying concentrations are added to the cells. The test agents are solubilized in 100% dimethylsulfoxide; the final dimethylsulfoxide concentration in the seeded plates does not exceed 0.1%. Completed plates are incubated for 3 days at 37° C. in a moisturized 7% CO 2 atmosphere. Cell survival is estimated by the sulforodoamine B assay (Skehan et al., 1990). Dye content/well is read at 540 nm in a microtiter reader.
- the vincristine resistant murine leukemia P388/VCR is propagated by intraperitoneal (IP) injection of 1 ⁇ 10 6 tumor cells into syngeneic DBA/2 mice (Charles River Laboratories, Inc.). Tumor cell ascites are harvested 5-7 days later.
- IP intraperitoneal
- groups of 10-15 CDFl mice DBA/2 ⁇ Balb/cFl hybrids; Charles River Laboratories, Inc) are injected IP with 0.5 ml of diluted ascitic fluid containing 1 ⁇ 10 6 viable P388/VCR tumor cells. All mice are of one sex, weighing a minimum of 18 g, and all with in a 3 g weight range per test.
- Drugs are administered once daily, by the IP, intravenous (IV) or oral route, starting one day after tumor implantation and using a variety of treatment schedules. Mice are weighed periodically, survival is recorded for 30 days post tumor implantation, and Mean survival times are calculated for all groups of mice. Statistical analysis of Mean survival times is carried out using the Student t-test. Positive MDR-1 drug resistance reversal activity is evidenced by a statistically significant (p ⁇ 0.05) increase in Mean survival time for groups of mice treated with vincristine plus MDR-1 compound, compared to groups of mice treated with an equivalent dose of vincristine alone.
- the multiple drug resistant human epidermoid carcinoma KB/8.5 is propagated in medium containing colchicine (10 nanograms/ml) to maintain drug resistance.
- Colchicine is removed from the medium, for two cell passages, prior to subcutaneous (SC) implant of 8 ⁇ 10 6 KB/8.5 tumor cells into athymic "nude" mice (Harlan Sprague Dawley).
- SC subcutaneous
- the SC tumors At this time (Day 0 of the test period) mice are allocated to treatment groups of 5-10 mice per group, so that the groups have a mean tumor mass as closely comparable as possible.
- Drug treatment is administered one day later, according to the following treatment protocol: doxorubicin is administered as a single intravenous dose (8 mg/kg), and either placebo (normal saline) or MDR-1 reversal compound is administered in two subcutaneous doses (12.5-200 mg/kg/dose) given 2 hours before and again at 2 hours after the single IV dose of doxorubicin.
- Individual mouse tumor mass and mean tumor mass for each treatment group is determined on Day +14 and Day +21 of the test period.
- the Relative Tumor Growth, RTG is calculated as follows: ##EQU1##
- the active ingredients of the therapeutic compositions and the novel compound of the present invention are effective modulators of a form of multiple drug resistance, commonly exhibited by human and animal tumors, that results from over-expression of the MDR-1 gene.
- these compounds When administered in combination with conventional antineoplastic chemotherapy, these compounds restore drug sensitivity to multiple drug resistant animal and human tumors resulting in significant increases in life span of leukemic animals and significant reduction in growth of human solid tumors implanted into experimental mammals.
- a preferred dosage regimen for optimum results would be from about 25 mg to about 200 mg per kilogram of body weight per day and such dosage units are employed that a total of from about 1.75 g to about 14 g of the active compound, for a subject of about 70 kg of body weight, are administered in a 24-hour period.
- This dosage may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or the total daily dose administered by slow constant infusion, or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- a decided practical advantage is that the active compounds may be administered by the oral, subcutaneous, intraperitoneal or intravenous routes.
- the active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixers, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of the unit.
- the amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.
- Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 200 mg. and 3.5 g of active compound.
- the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin
- a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring.
- tablets, pills, or capsules may be coated with shellac, sugar or both.
- a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and formulations.
- the active compounds may also be administered parenterally or intraperitoneally.
- Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a presevative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporanous preparation of sterile injectable solution or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contamination action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethyl alcohol, polyol (for example, glycerol, propylene glycol, cremophor and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatable with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
- the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically-acceptable carrier in dosage unit for as hereinbefore disclosed.
- a unit dosage form can, for example, contain the principal active compound in amounts ranging from about 200 mg. to about 3.5 g, with from about 500 mg. to 3.0 g being preferred. Expressed in proportions, the active compound is generally present in from about 200 mg. to about 3.5 g/ml of carrier.
- the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
- Regression and palliation of cancers are attained, for example, using intraperitoneal administration.
- a single intravenous dosage, slow constant infusion or repeated daily dosages can be administered.
- the duration of treatment will depend on the chemotherapeutic agent with which the compounds of claim 1 are administered.
- cancer disease means blood malignancies such as leukemia, as well as other solid and non-solid malignancies such as the melanocarcinomas, lung carcinomas, and mammary tumors.
- regression and palliation is meant arresting or retarding the growth of the tumor or other manifestation of the disease compared to the course of the disease in the absence of treatment.
- the organic solution is dried with magnesium sulfate, filtered and evaporated to give the crude product.
- the product is chromatographed on a column of silica gel and is eluted with ethyl acetate providing 1.6 g of the desired product, after evaporation of the solvent, as an orange gum.
- Example 3 The procedure of Example 3 is repeated using 1.0 g of ⁇ -(3-chloropropyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 0.76 g of 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline. This affords 0,253 g of the desired product as a beige gum.
- Example 4 The procedure of Example 4 is repeated using 0.19 g of ⁇ -(3,4-dimethoxyphenyl)-3,4-dihydro-6,7-dihydroxy-1-methyl- ⁇ -[(4-methylphenyl)thio]-2(1H)-isoquinolinepentanenitirle. This affords 0.144 g of the desired product as a light brown solid.
- Example 2 The procedure of Example 2 is repeated using 3.3 g of 4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzene-acetonitrile and 2.23 g of 1-chloro-4-bromobutane. This affords 3.18 g of the desired product as a colorless oil.
- Example 3 The procedure of Example 3 is repeated using 3.11 g of ⁇ -(4-chlorobutyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 1.84 g 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 1.83 g of the desired product as a brown oil.
- Example 3 The procedure of Example 3 is repeated using 3.3 g of ⁇ -(2-chloroethyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 1.14 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 0,311 g of the desired product as a brown oil.
- Example 2 The procedure of Example 2 is repeated using 3.79 g of 4-dimethoxy- ⁇ -[(4-methylphenyl)-thio]benzeneacetonitrile and 3.26 g of 1-bromo-3-chloro-2-methylpropane. This affords 4.13 g of the desired product as a light yellow oil.
- Example 2 The procedure of Example 2 is repeated using 4.0 g of ⁇ -(3-chloro-2-methylpropyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 3.5 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 0,985 g of the desired product as a yellow foam.
- Example 3 The procedure of Example 3 is repeated using 3.0 g of ⁇ -(3-chloropropyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile. This affords 0.84 g of the desired product as a colorless glass.
- Example 3 The procedure of Example 3 is repeated using 3.14 g of ⁇ -(11-bromoundecyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 2.03 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 2.2 g of the desired product as a light yellow oil.
- Example 3 The procedure of Example 3 is repeated using 2.1 g of ⁇ -(5-chloropentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 1.04 g of 1,2,3,4-tetrahydroisoquinoline. This affords 1.05 g of the desired product as a light brown gum.
- Example 3 The procedure of Example 3 is repeated using 4.65 g of ⁇ -(5-chloropentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 4.25 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. This affords 3.67 g of the desired product as a light brown gum.
- Example 4 The procedure of Example 4 is repeated using 0.2 g of ⁇ -(3,4-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy- ⁇ -[(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile. This affords 0,184 g of the desired product as white crystals.
- Example 13 The procedure of Example 13 is repeated using 0,869 g of 3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 1.6 mL of 1,8-dibromooctane. This affords 0,544 g of the desired product as a pale yellow oil.
- Example 3 The procedure of Example 3 is repeated using 0,836 g of ⁇ -(5-bromooctyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 0.675 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. This affords 0,422 g of the desired product as a brown gum.
- Example 3 The procedure of Example 3 is repeated using 0.854 g of ⁇ -(5-chloropentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]-benzeneacetonitrile and 0.677 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. This affords 0.701 g of the desired product.
- Example 3 The procedure of Example 3 is repeated using 2.05 g of ⁇ -( 5 -chloropentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 1.52 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline. This affords 1.25 g of the desired product as a brown oil.
- Nitrogen is bubbled through a stirred solution of 16.63 g of ⁇ -(5-aminopentyl)-3,4-dimethoxy- ⁇ [(4-methylphenyl)thio]benzeneacetonitrile, 10.12 g of 1,2-bischloromethyl-3,4-dimethoxybenzene (prepared by the procedure of J. H. Wood et. al., J.Am. Chem. Soc., 72, 2989(1950)), and 2.5 g of tetrabutylammonium chloride in 250 ml of toluene. A solution of 28 g of sodium hydroxide in 84 ml of water is added and the mixture is stirred vigorously for 48 hours.
- the crystals are recrystallized 2 times: first at a ratio of 1 g/4 ml of ethyl alcohol, second at a ratio of 1 g/5 ml of ethyl alcohol to give 9.38 g of the desired product as gray crystals.
- Example 3 The procedure of Example 3 is repeated using 2.5 g of ⁇ -(5-chloropentyl-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 2.54 g 7-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,4-tetrahydro-6-methoxyisoquinoline. This affords 1.2 g of the desired product as a light yellow oil.
- Example 4 The procedure of Example 4 is repeated using 1.77 g of ⁇ -(3,4-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy- ⁇ -[(4-methylphenyl)thio]-2(1H)-isoquinolinehexanenitrile. This affords 2.4 g of the desired product as a cream colored solid.
- Example 15 The procedure of Example 15 is repeated using 3.8 g of 3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 2.66 g of 1-bromo-5-chloroheaxane. This affords 4.35 g of the desired product as a colorless oil.
- Example 3 The procedure of Example 3 is repeated using 4.3 g of ⁇ -(5-chlorohexyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 4.25 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 3.05 g of the desired product as a golden gum.
- the reaction is concentrated in vacuo and the residual material is dissolved in ethyl acetate and is washed with brine. Drying (sodium sulfate) and solvent removal affords 33.22 g of oil. The residue is purified via chromatography on silica gel with gradient elution progressing from hexane to chloroform to methyl alcohol to afford 10.82 g of the desired product as a tan gum.
- Example 39 The procedure of Example 39 is repeated using 2.12 g of 4-[6-Bromo-1-[(4-methylphenyl)thio]hexyl]-1,2-dimethoxybenzene and 2.3 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 1.6 g of the desired product as a light yellow oil.
- the volatiles are removed at reduced pressure and the residue chromatographed on silica gel using a gradient elution of hexane to chloroform to methyl alcohol.
- the residue from the chromatography is dissolved in diethyl ether and passed through diatomaceous earth. This affords 4.4 g of the desired product as a yellow oil.
- Example 46 The procedure of Example 46 is repeated using 3.67 g of 4-[6-bromo-1-[(4-methylphenyl)thio]hexyl]-1,2-dimethoxybenzene in 40 mL of acetonitrile and 2.65 g of 6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline. This affords 4.13 g of the desired product as a yellow gum.
- Example 40 The procedure of Example 40 is repeated using 4.0 g of 1,2-dimethoxy-4-[[(4-methylphenyl)thio]-methyl]benzene and 46.15 g of 1,6 dibromohexane. This affords 36 g of the desired product as a yellow oil contaminated with 24.8% of the starting material, 1,2-dimethoxy-4-[[(4-methylphenyl)thio]methyl]benzene.
- Example 49 The procedure of Example 49 is repeated using 5.22 g of 4-[6-bromo-1-[(4-methylphenyl)thio]heptyl]-1,2-dimethoxybenzene, 3.29 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 2.49 g of the desired product as a yellow gum.
- Example 49 The procedure of Example 49 is repeated with 1.24 g of 6,7-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,4-tetrahydroisoquinoline and 1.83 g of 1-bromo-7-(3,4-dimethoxyphenyl)-7-[(4-dimethoxyphenyl)thio]heptane. This affords 2.0 g of the desired product as an orange oil.
- Example 49 The procedure of Example 49 is repeated using 0.345 g of tetrahydropapaverine hydrochloride and 0.30 g of ⁇ -(5-iodopentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile. This affords 0.263 g of the desired product as a yellow oil.
- a mixture of 2.5 g of ethyl 3,4-dimethoxy-E-oxo-benzene hexanoate and 16 mL of 10% alcoholic sodium hydroxide is stirred at room temperature for 3 hours.
- the mixture is diluted with water and the ethyl alcohol is removed at reduced pressure.
- the solution is acidified with concentrated hydrochloric acid.
- the solid obtained is collected by filtration, washed with water and dried to afford 2.2 g of the desired product as a beige solid.
- Example 3 The procedure of Example 3 is repeated using 2.7 g of ⁇ -(5-chloropentyl)- ⁇ -(cyclohexylthio)-3,4-dimethoxybenzeneacetonitrile and 2.53 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 2.5 g of the desired product as a light yellow oil.
- Example 60 The procedure of Example 60 is repeated using 1.4 g of 2-[6-(3,4-dimethoxyphenyl)-6-hydroxy]-1-oxo-hexyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline and 0.44 g of benzyl mercaptan. This affords 1.5 g of the desired product as a colorless oil.
- Example 61 The procedure of Example 61 is repeated using 1.4 g of 2-[6-(3,4-dimethoxyphenyl)-1-oxo-6-[(phenylmethyl)thio]hexyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline. This affords 1.15 g of the desired product as a colorless oil.
- Example 60 The procedure of Example 60 is repeated using 1.4 g of 2-[6-(3,4-dimethoxyphenyl)-6-hydroxy]-1-oxo-hexyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline and 0.42 mL of 2-methyl-2-propane thiol. This affords 1.4 g of the desired product as a white foam.
- Example 61 The procedure of Example 61 is repeated using 1.3 g of 2-[6-(3,4-dimethoxyphenyl)-6-[(1,1-dimethylethyl)thio]-1-oxohexyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline. This affords 1.08 g of the desired product a colorless oil.
- Example 49 The procedure of Example 49 is repeated using 5.31 g 4-[6-bromo-1-[(4-methylphenyl)thio]heptyl]-1,2-dimethoxybenzene, 3.29 g of 5,6-dimethoxyisoindoline and 2.65 g of 6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline. This affords 4.52 g of the desired product as a yellow oil.
- Hydrogen bromide gas is bubbled through a ice cooled suspension of 1.54 g of 3-hydroxy-4-methoxy-benzylalcohol in 50 ml of toluene.
- the reaction mixture is stirred with cooling until the solution is saturated, approximately 20 minutes.
- the solution is decanted from a reddish gum and the filtrate is concentrated in vacuo at a temperature below 40° C.
- the residue (1.84 g, 85%yield) is dissolved in 50 ml of toluene and added to a previously made room temperature mixture of 0.12 g of tetra-n-butylammonium bisulfate, 10 ml of 1N sodium hydroxide, 40 ml of water and 2.52 g of p-cresol to which 1.68 g of sodium bicarbonate has been added.
- the resultion 2-phase system is stirred over night at room temperature. The layers are separated and the organic phase is dried and concentrated in vacuo to give 3.27 g of crude product.
- the residue is dissolved in chloroform and washed with dilute hydrochloric acid, dried and concentrated in vacuo.
- Example 40 The procedure of Example 40 is repeated using 14.0 g of (1,1-dimethylethyl)[2-methoxy-5-[[4-methylphenyl)thio]methyl]phenoxy]dimethylsilane and 17.2 mL of 1,6 dibromohexane. This affords 15.94 g of the desired product as a yellow oil contaminated with 30% of the starting material, 1,2-dimethoxy-4-[[(4-methylphenyl)thio]methyl]benzene.
- Example 49 The procedure of Example 49 is repeated using 10.75 g of [5-[7-bromo-1-[(4-methylphenyl)thio]heptyl]-2-methoxyphenoxy](1,2-dimethylethyl)dimethylsilane and 11.5 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 10.6 g of desired product as a tan oil.
- the solvent is removed at reduced pressure and the residue chromatographed on silica gel with a gradient elution going from hexane to chloroform to methyl alcohol.
- the desired material is dissolved in diethyl ether and passed through a short hydrous magnesium silicate pad to afford after solvent removal 8.75 g of the desired product as a brown oil.
- the solvent is removed at reduced pressure and the residue chromatographed on silica gel with a gradient elution going from hexane to chloroform to methyl alcohol.
- the desired fractions are concentrated, dissolved in diethyl ether and passed through a short hydrous magnesium silicate pad.
- the solvent is removed at reduced pressure to afford 1.6 g of the desired product as a light tan gum.
- N,N-dimethylformamide To 0.76 g of imidazole in 5 mL of 4A sieve-dried N,N-dimethylformamide is added 0.18 g of 60% sodium hydride in oil. When the effervescence subsides, 0.26 g of sodium iodide is added, followed by 1.12 g of 2-[7-[3-(2-chloroethoxy)-4-methoxyphenyl]-7[(4-methylphenyl)thio]heptyl]-1,2,3,4-tetrahydro-6,7dimethoxyisoquinoline in 5 mL of N,N-dimethylformamide. An additional 2 mL of N,N-dimethylformamide is used as wash.
- Example 34 The procedure of Example 34 is used with 0.77 g of 1,2,3,4-tetrahydro-2-[7-[3-[2-(1H-imidazol-1-yl )ethoxy]-4-methoxyphenyl]-7-[(4-methylphenyl)thio]heptyl]-6,7-dimethoxyisoquinoline. This affords 0.32 g of the desired product as a yellow gum.
- Example 60 The procedure of Example 60 is repeated using of 2.7 g of 2-[6-(3,4-dimethoxyphenyl)-6-hydroxy-1-oxooctyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline and 1.06 g of p-thiocresol. This affords 1.92 g of the desired product as a white foam.
- Example 61 The procedure of Example 61 is repeated using 1.7 g of 2-[6-(3,4-dimethoxyphenyl]-6-[(4-methylphenyl)thio]-1-oxooctyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline. This affords 1.33 g of the desired product as a colorless oil.
- N-bromosuccinimde A 2.53 g portion of N-bromosuccinimde is added to 40 mL methylene chloride and 5 mL diethyl ether ether. The solution is cooled to 0° C. and 1.25 mL methyl sulfide is slowly added via a syringe. A yellow solid is formed. Following complete addition of the methyl sulfide, the reaction mixture is cooled to -20° C. To this is added 0.736 g of 4,5-dichloro-1,2-benzenedimethanol. The reaction mixture is warmed to 0° C. and stirred for 3 hours, followed by quenching with 30 mL of ice water. A further 30 mL of methylene chloride is added and the layers are separated.
- Example 27 The procedure of Example 27 is used with 0.52 g of ⁇ -(5-aminopentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 0.3 g of 1,2-bis(bromomethyl)-4,5-dichlorobenzene. This affords 0,475 g of the desired product as a yellow oil.
- Example 1 The procedure of Example 1 is repeated using 10.2 g of ⁇ -chloro-3,4-dimethoxybenzeneacetonitrile and 6.2 mL of cyclohexy mercaptan. This affords 7.8 g of the desired product as light yellow crystals.
- Example 2 The procedure of Example 2 is repeated using 3.0 g of ⁇ -(cyclohexylthio)-3,4-dimethoxy benzeneacetonitrile and 2.0 mL of bromo-5-chloropentane. This affords 3.1 g of the desired product as a colorless oil.
- Example 24 The procedure of Example 24 is repeated using 2.1 g of ⁇ -(5-chloropentyl)- ⁇ -(cyclohexylthio)-3,4-dimethoxybenzeneacetonitrile and 0,954 g of the potassium salt of phthalimide. This affords 2.13 g of the desired product as a colorless oil.
- Example 25 The procedure of Example 25 is repeated using 2.0 g of ⁇ -(cyclohexylthio)- ⁇ -(3,4-dimethoxyphenyl)-1,3-dioxo-2H-isoindol ⁇ -2-heptanenitrile and 3.0 mL of hydrazine hydrate. This affords 1.32 g of the desired product as a light yellow oil.
- Example 40 The procedure of Example 40 is repeated using 23.44 g of 5-[[(4-methylphenyl)thio]methyl]-1,3-benzodioxole and 24.7 mL of 1,5-dibromopentane. This affords 23 g of the desired product as a clear oil.
- Example 49 The procedure of Example 49 is repeated using 4.07 g of the 5-[6-bromo-1-[(4-methylphenyl)thio]hexyl-1,3-benzodioxole and 4.6g of 4.6 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 4.2 g of the desired product as a yellow oil.
- Example 87 The procedure of Example 87 is repeated using 1.8 g of p-thiocresol and 9.6 g of 4-(trifluoromethoxy)benzyl chloride. This affords 10.9 g of the desired product as white crystals.
- Example 40 The procedure of Example 40 is repeated using 9.95 g of 1-[[(4-methylphenyl)thio]methyl]-4-(trifluoromethoxy)benzene and 23.0 g of 1,5-dibromopentane. This affords 13.0 g of the desired product as a yellow gum.
- Example 46 The procedure of Example 46 is repeated using 7.16 g of 1-[6-bromo-1-[(methylphenyl)thio]hexyl]-4-(trifluoromethoxy)benzene and 4.6 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinloine hydrochloride. This affords 6.24 g of the desired product as a yellow gum.
- Example 40 The procedure of Example 40 is repeated using 1.39 g of 1-fluoro-4-[[4-methylphenyl)thio]methyl]benzene and 4.5 mL of 1,6-dibromohexane. This affords 0.49 g of the desired product as a yellow semisolid.
- Example 3 The procedure of Example 3 is repeated using 0.49 g of the 1-[[6-bromo-1-(4-fluorophenyl)hexyl]thio]-4-methylbenzene and 0,284 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride. This affords 0.457 g of the desired product as a colorless oil.
- Example 3 The procedure of Example 3 is repeated using 0.89 g of ⁇ -(5-chloropentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile and 0.56 g of 1,2,3,4-tetrahydro-6-methoxy-7-(phenylmethoxy) isoquinoline hydrochloride. This affords 0.5 g of the desired product as a colorless gum.
- the aqueous phase is extracted with 2 ⁇ 20 mL diethyl ether.
- the combined organic layers are washed with 20 mL brine, and dried over magnesium sulfate.
- the product is purified by silica gel chromatography (eluting with 2:1 hexane/ethyl acetate) to produce 4.15 g of the desired product as a white solid.
- the aqueous layer is further extracted with 30 mL dielthyl ether.
- the combined organic layers are washed with 20 mL water and brine successively, and dried over magnesium sulfate.
- the product is purified by silica gel chromatography (eluting with 95:5 methylene chloride/methyl alcohol) to produce 0.402 g of the desired product as a white foam.
- This oil is taken up in diethyl ether and passed through a short pad of hydrous magnesium silicate with 400 mL of diethyl ether. The volatiles are removed and the residual oil purified using 4% ethyl acetate in hexane. This affords 1.36 g of the desired product as a white fluffy solid.
- Example 26 The procedure of Example 26 is repeated using 1.0 g of bis(chloromethyl)-4-methoxy-5-(phenylmethoxy)benzene and 0.6 mL of benzyl amine. This affords 0.74 g of the desired product as a beige solid.
- Example 49 The procedure of Example 49 is used with 0.209 g of 2,3-dihydro-6-methoxy-1H-isoindol-5-ol (Example 105) and 0.57 g of ⁇ -(5-bromopentyl)-3,4-dimethoxy- ⁇ -[(4-methylphenyl)thio]benzeneacetonitrile. This affords 0.5 g of the desired product as a gray foam.
- Example of 32 The procedure of Example of 32 is used with 0.45 g of ⁇ -(3,4-dimethoxyphenyl)-1,3-dihydro-5-hydroxy-6-methoxy- ⁇ -[(4-methylphenyl)thio]-2H-isoindole-2-heptanenitrile and 0.65 g of 2-chloroethyl p-toluenesulfonate. This affords 0.367 g of the desired product as a light brown oil.
- the solution is cooled and and poured into water.
- the solution is extracted with ethyl acetate and the organic layer washed with brine and dried over sodium sulfate.
- the solvent is removed at reduce pressure and the residual oil purified via column chromatography using a gradient elution from 4% methyl alcohol in methylene chloride to 9% methyl alcohol in methylene chloride. This affords 0.196 g of the desired product as a beige oil.
- the resulting yellow solution is transferred, under nitrogen via canula to a cooled, -78° C., second flask charged with 38.5 ml of 1,6-dibromohexane in 400 ml of diethyl ether (200 ml of tetrahydrofuran needed to maintain a homogenous solution). After the addition, the reaction mixture is allowed to warm to room temperature over 4 hours. Ten ml of ethyl acetate and 10 ml of 2-propanol is added and the reaction is concentrated in vacuo. The white oily residue is dissolved in chloroform, washed with dilute hydrobromic acid and saturated sodium chloride, dried and concentrated in vacuo to give 74.6 g of crude product. The crude product was purified 3X by chromatography (hexane to chloroform to methyl alcohol) to give 29.26 g of pure product.
- a mixture, under argon, of 2.17 g of product from Example 113, 1.8 g of product from Example 28, 13.0 ml of N,N-diidopropyl ethylamine and 80 ml of acetonitrile is heated under reflux temperature for 8 hours.
- the reaction is cooled and concentrated in vacuo and dried under high vacuum for 1 hour.
- the crude residue is dissolved in 70 ml of tetrahydrofuran and 10.0 ml of 1M tetrabutyl ammonium fluoride in tetrahydrofuran is added and the mixture is stirred at room temperature, under argon, for 2.5 hours.
- the mixture is poured into water and extracted with ethyl acetate.
- the oil is purified by chromatography (silica gel: 2, 4, 6, 8 and 10% methyl alcohol/methylene chloride) to give 1.27 g of a beige foam.
- the foam is dissolved in 3.0 ml of ethyl alcohol and 1.2 ml of 4.5M hydrogen chloride in ethyl alcohol is added.
- the mixture is stirred and diethyl ether is added.
- the reaction mixture is kept in the refrigerator overnight.
- the supernatant is decanted, the oil triturated with diethyl ether and left in the refrigerator for 48 hours.
- the solid is collected, washed with diethyl ether and dried for 3 hours at 40° C. under high vacuum to give 1.29 g of the desired product as a white solid.
- Example 113 The title compound is prepared by the procedure of Example 113 using 1.3 g of product from Example 117, 0,218 g of 50% sodium hydride, 2.15 g of 1,5-dibromopentane and 16 ml of dimethyl sulfoxide to give after chromatography 1.61 g of the desired product as a yellow oil.
- Example 121 The title compound is prepared by the procedure of Example 121 using 1.5 g of product from Example 121 in 35 ml of tetrahydrofuran, 4.0 ml of 1.0M sodium hexamethyldisilazide, and 1.0 g of p-tolyldisulfide to give 0.9 g of the desired product.
- reaction mixture is concentrated in vacuo and the residue partitioned between ethyl acetate and water.
- the organic layer is washed with saturated sodium chloride, dried and concentrated in vacuo.
- the residue is purified by chromatography (silica gel: methylene chloride/methyl alcohol, 95/5) to give 0.12 g of the desired product.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Gyroscopes (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Cephalosporin Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Permanent Magnet Type Synchronous Machine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (31)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/092,653 US5387685A (en) | 1993-07-16 | 1993-07-16 | MDR reversal agents |
CZ941572A CZ157294A3 (en) | 1993-07-16 | 1994-06-27 | Ndr reversible agents |
ES94110067T ES2109554T3 (es) | 1993-07-16 | 1994-06-29 | Agentes de reversion de la resistencia a multiples farmacos. |
AT94110067T ATE156816T1 (de) | 1993-07-16 | 1994-06-29 | Multiwirkstoffresistenz-umkehrende mittel |
DK94110067.9T DK0634401T3 (da) | 1993-07-16 | 1994-06-29 | MDR-reverserende midler |
SI9430091T SI0634401T1 (en) | 1993-07-16 | 1994-06-29 | MDR reversal agents |
SG1996003580A SG47662A1 (en) | 1993-07-16 | 1994-06-29 | Mdr reversal agents |
DE69404917T DE69404917T2 (de) | 1993-07-16 | 1994-06-29 | Multiwirkstoffresistenz-umkehrende Mittel |
EP94110067A EP0634401B1 (en) | 1993-07-16 | 1994-06-29 | MDR reversal agents |
SK795-94A SK79594A3 (en) | 1993-07-16 | 1994-07-01 | Agents for renovation of sensitivity of cells resistant towards some agents |
PH48607A PH30780A (en) | 1993-07-16 | 1994-07-12 | MDR reversal agents. |
IL11029494A IL110294A0 (en) | 1993-07-16 | 1994-07-12 | MDR reversal agents |
EC1994001118A ECSP941118A (es) | 1993-07-16 | 1994-07-13 | Agentes de invercion mdr |
PE1994246523A PE4495A1 (es) | 1993-07-16 | 1994-07-13 | Agente resensibilizante de celulas resistentes a drogas multiples y procedimiento de preparacion |
JP6183008A JPH07179422A (ja) | 1993-07-16 | 1994-07-13 | Mdr逆転剤 |
CA002128139A CA2128139A1 (en) | 1993-07-16 | 1994-07-14 | Mdr reversal agents |
NZ264013A NZ264013A (en) | 1993-07-16 | 1994-07-15 | Benzoazacycloalkyl-alkyl or -methylphenylmethyl substituted benzyl thioether derivatives and pharmaceutical compositions |
AU67501/94A AU691495B2 (en) | 1993-07-16 | 1994-07-15 | MDR reversal agents |
RU94026288/04A RU94026288A (ru) | 1993-07-16 | 1994-07-15 | Новые соединения как средства подавления полилекарственной резистентности, способы их получения, фармацевтическая композиция, способ лечения |
NO942673A NO303173B1 (no) | 1993-07-16 | 1994-07-15 | MDR-reverseringsmidler |
KR1019940017168A KR950003274A (ko) | 1993-07-16 | 1994-07-15 | 복합약 내성 역전제로서 신규한 비시클릭아민 화합물 |
ZA945211A ZA945211B (en) | 1993-07-16 | 1994-07-15 | Mdr reversal agents |
HU9402111A HU218478B (hu) | 1993-07-16 | 1994-07-15 | Biciklikus aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények |
FI943392A FI943392A (fi) | 1993-07-16 | 1994-07-15 | MDR:ään käänteisesti vaikuttavia aineita |
PL94304320A PL304320A1 (en) | 1993-07-16 | 1994-07-15 | Agents causing reversion of multiple drug-resistance |
CN94108463A CN1049891C (zh) | 1993-07-16 | 1994-07-16 | 双环胺类化合物及其制备方法和含该化合物的药物组合物 |
TW083108369A TW302360B (es) | 1993-07-16 | 1994-09-10 | |
US08/328,643 US5550149A (en) | 1993-07-16 | 1994-10-25 | MDR reversal agents |
US08/449,972 US5561141A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
US08/450,172 US5639887A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
GR970402747T GR3025105T3 (en) | 1993-07-16 | 1997-10-20 | MDR reversal agents. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/092,653 US5387685A (en) | 1993-07-16 | 1993-07-16 | MDR reversal agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/328,643 Division US5550149A (en) | 1993-07-16 | 1994-10-25 | MDR reversal agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US5387685A true US5387685A (en) | 1995-02-07 |
Family
ID=22234360
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/092,653 Expired - Fee Related US5387685A (en) | 1993-07-16 | 1993-07-16 | MDR reversal agents |
US08/328,643 Expired - Fee Related US5550149A (en) | 1993-07-16 | 1994-10-25 | MDR reversal agents |
US08/450,172 Expired - Fee Related US5639887A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
US08/449,972 Expired - Fee Related US5561141A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/328,643 Expired - Fee Related US5550149A (en) | 1993-07-16 | 1994-10-25 | MDR reversal agents |
US08/450,172 Expired - Fee Related US5639887A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
US08/449,972 Expired - Fee Related US5561141A (en) | 1993-07-16 | 1995-05-25 | MDR reversal agents |
Country Status (28)
Country | Link |
---|---|
US (4) | US5387685A (es) |
EP (1) | EP0634401B1 (es) |
JP (1) | JPH07179422A (es) |
KR (1) | KR950003274A (es) |
CN (1) | CN1049891C (es) |
AT (1) | ATE156816T1 (es) |
AU (1) | AU691495B2 (es) |
CA (1) | CA2128139A1 (es) |
CZ (1) | CZ157294A3 (es) |
DE (1) | DE69404917T2 (es) |
DK (1) | DK0634401T3 (es) |
EC (1) | ECSP941118A (es) |
ES (1) | ES2109554T3 (es) |
FI (1) | FI943392A (es) |
GR (1) | GR3025105T3 (es) |
HU (1) | HU218478B (es) |
IL (1) | IL110294A0 (es) |
NO (1) | NO303173B1 (es) |
NZ (1) | NZ264013A (es) |
PE (1) | PE4495A1 (es) |
PH (1) | PH30780A (es) |
PL (1) | PL304320A1 (es) |
RU (1) | RU94026288A (es) |
SG (1) | SG47662A1 (es) |
SI (1) | SI0634401T1 (es) |
SK (1) | SK79594A3 (es) |
TW (1) | TW302360B (es) |
ZA (1) | ZA945211B (es) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
US5994130A (en) * | 1997-04-16 | 1999-11-30 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
US6150398A (en) * | 1991-05-08 | 2000-11-21 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the treatment of cancer |
US6235785B1 (en) | 1994-08-31 | 2001-05-22 | Eli Lilly And Company | Methods for identifying and treating resistant tumors |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US20020169111A1 (en) * | 1998-05-27 | 2002-11-14 | American Cyanamid Comany | Reversal of multidrug resistance in human colon carcinoma cells |
US20050020573A1 (en) * | 2002-04-12 | 2005-01-27 | Arena Pharmaceuticals, Inc. | 5HT2c receptor modulators |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
US20070142357A1 (en) * | 2003-06-17 | 2007-06-21 | Brian Smith | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US20070275949A1 (en) * | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
US20080045502A1 (en) * | 2003-06-17 | 2008-02-21 | Arena Pharmaceuticals, Inc. | Processes for Preparing 3-Benzazepines |
US20090143576A1 (en) * | 2006-04-03 | 2009-06-04 | Ulrich Weigl | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto |
US20090197868A1 (en) * | 2004-12-23 | 2009-08-06 | Behan Dominic P | 5ht2c receptor modulator compositions and methods of use |
US20100305316A1 (en) * | 2006-12-05 | 2010-12-02 | Tawfik Gharbaoui | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
US20110015438A1 (en) * | 2008-03-04 | 2011-01-20 | Carlos Marlon V | Process for the preparation of intermediates related tothe 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5,-tetrahydro-1h-3-benzazepine |
US8168624B2 (en) | 2004-12-21 | 2012-05-01 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
US9169213B2 (en) | 2012-10-09 | 2015-10-27 | Arena Pharmaceuticals, Inc. | Method of weight management |
US9248133B2 (en) | 2010-09-01 | 2016-02-02 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
US9365521B2 (en) | 2010-09-01 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
US9771316B2 (en) | 2013-01-21 | 2017-09-26 | Osaka University | Phenoxyalkylamine compound |
US10226471B2 (en) | 2010-09-01 | 2019-03-12 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726184A (en) * | 1995-05-19 | 1998-03-10 | Vertex Pharmaceuticals Incorporated | Tetralin compounds with improved MDR activity |
JP2942824B1 (ja) * | 1998-03-13 | 1999-08-30 | 工業技術院長 | シリルチオアルケン化合物及びその製造方法 |
US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
ATE441417T1 (de) | 2002-12-20 | 2009-09-15 | Glaxo Group Ltd | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten |
CA2539729C (en) | 2003-09-23 | 2010-09-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
CA2539853C (en) | 2003-09-23 | 2011-04-19 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
AU2018347537A1 (en) | 2017-10-13 | 2020-04-02 | Scholl's Wellness Company Llc | Footcare product dispensing kiosk |
CN110240554B (zh) * | 2019-06-27 | 2021-02-23 | 上海大学 | α-硫醚芳基乙腈类化合物及其合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2969362A (en) * | 1959-08-11 | 1961-01-24 | Searle & Co | 2-[alpha-(haloalkyl) benzylthio] imidazolines and tetrahydropyrimidines corresponding |
US4792559A (en) * | 1985-10-04 | 1988-12-20 | Adir Et Compagnie | 1,2,3,4-tetrahydroquinoline substituted 5-aminopentanenitrile compounds and their use as calcium modulators |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4833162A (en) * | 1988-02-03 | 1989-05-23 | American Cyanamid Company | Substituted benzeneacetonitriles and their use as calcium channel blockers |
IE902182A1 (en) * | 1989-06-19 | 1991-01-02 | Wellcome Found | Medicaments |
AU652996B2 (en) * | 1991-01-11 | 1994-09-15 | Laboratoires Glaxo S.A. | Acridine derivatives |
FR2673627B1 (fr) * | 1991-03-07 | 1993-05-07 | Adir | Triazines et pyrimidines trisubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
DK0649410T3 (da) * | 1992-07-10 | 1997-09-15 | Glaxo Lab Sa | Anilidderivater. |
-
1993
- 1993-07-16 US US08/092,653 patent/US5387685A/en not_active Expired - Fee Related
-
1994
- 1994-06-27 CZ CZ941572A patent/CZ157294A3/cs unknown
- 1994-06-29 AT AT94110067T patent/ATE156816T1/de not_active IP Right Cessation
- 1994-06-29 DK DK94110067.9T patent/DK0634401T3/da active
- 1994-06-29 DE DE69404917T patent/DE69404917T2/de not_active Expired - Fee Related
- 1994-06-29 SG SG1996003580A patent/SG47662A1/en unknown
- 1994-06-29 EP EP94110067A patent/EP0634401B1/en not_active Expired - Lifetime
- 1994-06-29 ES ES94110067T patent/ES2109554T3/es not_active Expired - Lifetime
- 1994-06-29 SI SI9430091T patent/SI0634401T1/xx unknown
- 1994-07-01 SK SK795-94A patent/SK79594A3/sk unknown
- 1994-07-12 IL IL11029494A patent/IL110294A0/xx unknown
- 1994-07-12 PH PH48607A patent/PH30780A/en unknown
- 1994-07-13 EC EC1994001118A patent/ECSP941118A/es unknown
- 1994-07-13 PE PE1994246523A patent/PE4495A1/es not_active Application Discontinuation
- 1994-07-13 JP JP6183008A patent/JPH07179422A/ja active Pending
- 1994-07-14 CA CA002128139A patent/CA2128139A1/en not_active Abandoned
- 1994-07-15 KR KR1019940017168A patent/KR950003274A/ko not_active Application Discontinuation
- 1994-07-15 RU RU94026288/04A patent/RU94026288A/ru unknown
- 1994-07-15 ZA ZA945211A patent/ZA945211B/xx unknown
- 1994-07-15 FI FI943392A patent/FI943392A/fi unknown
- 1994-07-15 PL PL94304320A patent/PL304320A1/xx unknown
- 1994-07-15 NZ NZ264013A patent/NZ264013A/en unknown
- 1994-07-15 NO NO942673A patent/NO303173B1/no not_active IP Right Cessation
- 1994-07-15 AU AU67501/94A patent/AU691495B2/en not_active Ceased
- 1994-07-15 HU HU9402111A patent/HU218478B/hu not_active IP Right Cessation
- 1994-07-16 CN CN94108463A patent/CN1049891C/zh not_active Expired - Fee Related
- 1994-09-10 TW TW083108369A patent/TW302360B/zh active
- 1994-10-25 US US08/328,643 patent/US5550149A/en not_active Expired - Fee Related
-
1995
- 1995-05-25 US US08/450,172 patent/US5639887A/en not_active Expired - Fee Related
- 1995-05-25 US US08/449,972 patent/US5561141A/en not_active Expired - Fee Related
-
1997
- 1997-10-20 GR GR970402747T patent/GR3025105T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2969362A (en) * | 1959-08-11 | 1961-01-24 | Searle & Co | 2-[alpha-(haloalkyl) benzylthio] imidazolines and tetrahydropyrimidines corresponding |
US4792559A (en) * | 1985-10-04 | 1988-12-20 | Adir Et Compagnie | 1,2,3,4-tetrahydroquinoline substituted 5-aminopentanenitrile compounds and their use as calcium modulators |
Non-Patent Citations (3)
Title |
---|
Mukaiyama, T. et al., Chem. Lett., 11:1177 80 (1976). * |
Mukaiyama, T. et al., Chem. Lett., 11:1177-80 (1976). |
The Merck Index, Martha Windholz, editor, Ninth edition, 1976. * |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150398A (en) * | 1991-05-08 | 2000-11-21 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the treatment of cancer |
US6235785B1 (en) | 1994-08-31 | 2001-05-22 | Eli Lilly And Company | Methods for identifying and treating resistant tumors |
US6673813B2 (en) | 1994-08-31 | 2004-01-06 | Gabriele Jedlitschky | Methods for identifying and treating resistant tumors |
US20040176439A1 (en) * | 1995-10-26 | 2004-09-09 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability or pharmaceutical agents |
US7041640B2 (en) | 1995-10-26 | 2006-05-09 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US20070060635A1 (en) * | 1995-10-26 | 2007-03-15 | Teva North America | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6610735B2 (en) | 1995-10-26 | 2003-08-26 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US20050238634A1 (en) * | 1995-10-26 | 2005-10-27 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US6730698B2 (en) | 1995-10-26 | 2004-05-04 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US20040171532A1 (en) * | 1995-10-26 | 2004-09-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6936583B2 (en) | 1995-10-26 | 2005-08-30 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6818615B2 (en) | 1995-10-26 | 2004-11-16 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
US7785812B2 (en) | 1997-04-16 | 2010-08-31 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
US20050191307A1 (en) * | 1997-04-16 | 2005-09-01 | Shyjan Andrew W. | Novel multidrug resistance-associated polypeptide |
US5994130A (en) * | 1997-04-16 | 1999-11-30 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
US6162616A (en) * | 1997-04-16 | 2000-12-19 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
US8287862B2 (en) | 1997-04-16 | 2012-10-16 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
US20110020341A1 (en) * | 1997-04-16 | 2011-01-27 | Millennium Pharmaceuticals, Inc. | Novel multidrug resistance-associated polypeptide |
US6878737B2 (en) | 1998-05-27 | 2005-04-12 | Wyeth Holdings Corporation | Reversal of multidrug resistance in human colon carcinoma cells |
US20020169111A1 (en) * | 1998-05-27 | 2002-11-14 | American Cyanamid Comany | Reversal of multidrug resistance in human colon carcinoma cells |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
US7977329B2 (en) | 2002-04-12 | 2011-07-12 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US8207158B2 (en) | 2002-04-12 | 2012-06-26 | Arena Pharmaceuticals, Inc. | 5HT2c receptor modulators |
US8575149B2 (en) | 2002-04-12 | 2013-11-05 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7514422B2 (en) | 2002-04-12 | 2009-04-07 | Arena Pharmaceuticals, Inc. | 5HT2c receptor modulators |
US8546379B2 (en) | 2002-04-12 | 2013-10-01 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US20050020573A1 (en) * | 2002-04-12 | 2005-01-27 | Arena Pharmaceuticals, Inc. | 5HT2c receptor modulators |
US8846906B2 (en) | 2002-04-12 | 2014-09-30 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US20070060568A1 (en) * | 2002-04-12 | 2007-03-15 | Arena Pharmaceuticals, A Delaware Corporation | 5HT2c receptor modulators |
US8273734B1 (en) | 2002-04-12 | 2012-09-25 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US8993750B2 (en) | 2002-04-12 | 2015-03-31 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US20100173894A1 (en) * | 2003-06-17 | 2010-07-08 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US7704993B2 (en) | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US20080045502A1 (en) * | 2003-06-17 | 2008-02-21 | Arena Pharmaceuticals, Inc. | Processes for Preparing 3-Benzazepines |
US9102627B2 (en) | 2003-06-17 | 2015-08-11 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US8404675B2 (en) | 2003-06-17 | 2013-03-26 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases |
US8946207B2 (en) | 2003-06-17 | 2015-02-03 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US8367657B2 (en) | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US20070142357A1 (en) * | 2003-06-17 | 2007-06-21 | Brian Smith | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US20070275949A1 (en) * | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
US8980881B2 (en) | 2004-12-21 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
US8168624B2 (en) | 2004-12-21 | 2012-05-01 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
US8697686B2 (en) | 2004-12-21 | 2014-04-15 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
US20090197868A1 (en) * | 2004-12-23 | 2009-08-06 | Behan Dominic P | 5ht2c receptor modulator compositions and methods of use |
US8153621B2 (en) | 2004-12-23 | 2012-04-10 | Arena Pharmaceuticals, Inc. | 5ht2C receptor modulator compositions |
US8546378B2 (en) | 2004-12-23 | 2013-10-01 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulator compositions and methods of use |
US8802845B2 (en) | 2006-04-03 | 2014-08-12 | Arena Phamaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto |
US8501935B2 (en) | 2006-04-03 | 2013-08-06 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto |
US8168782B2 (en) | 2006-04-03 | 2012-05-01 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto |
US20090143576A1 (en) * | 2006-04-03 | 2009-06-04 | Ulrich Weigl | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto |
US8299241B2 (en) | 2006-12-05 | 2012-10-30 | Arena Pharmaceuticals, Inc. | Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof |
US20100305316A1 (en) * | 2006-12-05 | 2010-12-02 | Tawfik Gharbaoui | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
US20110015438A1 (en) * | 2008-03-04 | 2011-01-20 | Carlos Marlon V | Process for the preparation of intermediates related tothe 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5,-tetrahydro-1h-3-benzazepine |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
US8999970B2 (en) | 2010-09-01 | 2015-04-07 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
US9248133B2 (en) | 2010-09-01 | 2016-02-02 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
US9365521B2 (en) | 2010-09-01 | 2016-06-14 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-HT2C agonists |
US9770455B2 (en) | 2010-09-01 | 2017-09-26 | Arena Pharmaceuticals, Inc. | Administration of an anti-obesity compound to individuals with renal impairment |
US10226471B2 (en) | 2010-09-01 | 2019-03-12 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
US10463676B2 (en) | 2010-09-01 | 2019-11-05 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
US9169213B2 (en) | 2012-10-09 | 2015-10-27 | Arena Pharmaceuticals, Inc. | Method of weight management |
US9771316B2 (en) | 2013-01-21 | 2017-09-26 | Osaka University | Phenoxyalkylamine compound |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5387685A (en) | MDR reversal agents | |
EP1786773B1 (en) | Isoindolin-1-one derivatives | |
US7229986B2 (en) | Melanin-concentrating hormone antagonist | |
US5403847A (en) | Use of α1C specific compounds to treat benign prostatic hyperlasia | |
KR100422286B1 (ko) | Cetp억제제로서의 4-아미노치환-2-치환-1,2,3,4-테트라히드로퀴놀린 | |
JP2002526477A (ja) | Cetp阻害剤としての4−カルボキシアミノ−2−メチル−1,2,3,4−テトラヒドロキノリン類 | |
US4988690A (en) | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof | |
KR0165131B1 (ko) | 1,4-벤조티아제핀 유도체 | |
US5385914A (en) | Cardiotonic carbostyril agents for treating heart ailments | |
US5607934A (en) | Piperazine derivatives and salts thereof | |
CA2378499A1 (en) | Cyclic amine ccr3 antagonists | |
US5508306A (en) | Aromatic amine derivatives | |
CA2630655C (fr) | Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu'antagonistes du recepteur de l'histamine h3 | |
US5935955A (en) | Pharmaceutical piperazine compounds | |
SU1598875A3 (ru) | Способ получени производных тетрагидроизохинолина или их фармацевтически приемлемых кислотно-аддитивных солей | |
HU186654B (en) | Process for producing new pyridine derivatives, acid additional salts and quaternary salts and pharmaceutical compositions containing them | |
US5102894A (en) | Substituted piperidine compounds and their use | |
US5198448A (en) | Cardiotonics | |
US5266577A (en) | Method of treating congestive heart failure using carbostyril derivatives | |
US4935418A (en) | Medical compositions of 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and use thereof | |
KR820001235B1 (ko) | 알킬티오페녹시프로파놀아민의 제조방법 | |
JP2719740B2 (ja) | 強心剤 | |
JP2000169462A (ja) | N,n―置換環状アミン誘導体 | |
JPH05239030A (ja) | アミノメチルテトラヒドロイソキノリン誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AMERICAN CYANAMID COMPANY, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POWELL, DENNIS;PAUL, ROLF;HALLETT, WILLIAM A.;AND OTHERS;REEL/FRAME:006664/0247 Effective date: 19930713 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20030207 |